drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
listlengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00682 | DB01234 | 126 | 1,220 | [
"DDInter1951",
"DDInter513"
] | Warfarin | Dexamethasone | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Moderate | 1 | [
[
[
126,
24,
1220
]
],
[
[
126,
24,
870
],
[
870,
1,
1220
]
],
[
[
126,
63,
175
],
[
175,
40,
1220
]
],
[
[
126,
24,
617
],
[
617,
40,
1220
]
],
[
[
126,
63,
1573
],
[
1573,
1,
1220
]
],
[
[
126,
6,
10215
],
[
10215,
45,
1220
]
],
[
[
126,
7,
2384
],
[
2384,
46,
1220
]
],
[
[
126,
23,
271
],
[
271,
62,
1220
]
],
[
[
126,
24,
1072
],
[
1072,
23,
1220
]
],
[
[
126,
63,
1461
],
[
1461,
23,
1220
]
]
] | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Warfarin",
"{u} (Compound) upregulates {v} (Gene)",
"CDK6"
],
[
"CDK6",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
]
] | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Dexamethasone (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Dexamethasone (Compound)
Warfarin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Dexamethasone (Compound)
Warfarin (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Dexamethasone (Compound)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Dexamethasone |
DB00758 | DB11652 | 1,347 | 1,155 | [
"DDInter413",
"DDInter1891"
] | Clopidogrel | Tucatinib | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens. | Major | 2 | [
[
[
1347,
25,
1155
]
],
[
[
1347,
24,
222
],
[
222,
23,
1155
]
],
[
[
1347,
24,
609
],
[
609,
24,
1155
]
],
[
[
1347,
62,
522
],
[
522,
24,
1155
]
],
[
[
1347,
64,
126
],
[
126,
24,
1155
]
],
[
[
1347,
25,
1047
],
[
1047,
24,
1155
]
],
[
[
1347,
24,
738
],
[
738,
63,
1155
]
],
[
[
1347,
63,
168
],
[
168,
24,
1155
]
],
[
[
1347,
25,
1421
],
[
1421,
63,
1155
]
],
[
[
1347,
25,
1618
],
[
1618,
25,
1155
]
]
] | [
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tucatinib"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
]
] | Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Clopidogrel may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Clopidogrel may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Clopidogrel may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Clopidogrel may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Tucatinib |
DB00816 | DB00983 | 1,674 | 480 | [
"DDInter1346",
"DDInter776"
] | Orciprenaline | Formoterol | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting muscarinic antagonists.[L10992,L10989] | Moderate | 1 | [
[
[
1674,
24,
480
]
],
[
[
1674,
35,
1148
],
[
1148,
63,
480
]
],
[
[
1674,
1,
11540
],
[
11540,
40,
480
]
],
[
[
1674,
64,
1523
],
[
1523,
25,
480
]
],
[
[
1674,
5,
11649
],
[
11649,
44,
480
]
],
[
[
1674,
6,
3576
],
[
3576,
45,
480
]
],
[
[
1674,
54,
19240
],
[
19240,
15,
480
]
],
[
[
1674,
21,
28719
],
[
28719,
60,
480
]
],
[
[
1674,
62,
218
],
[
218,
23,
480
]
],
[
[
1674,
23,
423
],
[
423,
62,
480
]
]
] | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Orciprenaline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Orciprenaline",
"{u} (Compound) resembles {v} (Compound)",
"Fenoterol"
],
[
"Fenoterol",
"{u} (Compound) resembles {v} (Compound)",
"Formoterol"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Formoterol"
]
],
[
[
"Orciprenaline",
"{u} (Compound) treats {v} (Disease)",
"asthma"
],
[
"asthma",
"{u} (Disease) is treated by {v} (Compound)",
"Formoterol"
]
],
[
[
"Orciprenaline",
"{u} (Compound) binds {v} (Gene)",
"ADRB2"
],
[
"ADRB2",
"{u} (Gene) is bound by {v} (Compound)",
"Formoterol"
]
],
[
[
"Orciprenaline",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Adrenergic beta2-Agonists"
],
[
"Adrenergic beta2-Agonists",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Formoterol"
]
],
[
[
"Orciprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Formoterol"
]
],
[
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Beclomethasone dipropionate"
],
[
"Beclomethasone dipropionate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Formoterol"
]
],
[
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ciclesonide"
],
[
"Ciclesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Formoterol"
]
]
] | Orciprenaline (Compound) resembles Isoprenaline (Compound) and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Orciprenaline (Compound) resembles Fenoterol (Compound) and Fenoterol (Compound) resembles Formoterol (Compound)
Orciprenaline may lead to a major life threatening interaction when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Formoterol
Orciprenaline (Compound) treats asthma (Disease) and asthma (Disease) is treated by Formoterol (Compound)
Orciprenaline (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Formoterol (Compound)
Orciprenaline (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Formoterol (Compound)
Orciprenaline (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Formoterol (Compound)
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Beclomethasone dipropionate and Beclomethasone dipropionate may cause a minor interaction that can limit clinical effects when taken with Formoterol
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Ciclesonide and Ciclesonide may cause a minor interaction that can limit clinical effects when taken with Formoterol |
DB00108 | DB08895 | 1,066 | 976 | [
"DDInter1268",
"DDInter1825"
] | Natalizumab | Tofacitinib | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Major | 2 | [
[
[
1066,
25,
976
]
],
[
[
1066,
23,
1193
],
[
1193,
62,
976
]
],
[
[
1066,
23,
1461
],
[
1461,
23,
976
]
],
[
[
1066,
24,
200
],
[
200,
63,
976
]
],
[
[
1066,
24,
1430
],
[
1430,
24,
976
]
],
[
[
1066,
25,
652
],
[
652,
64,
976
]
],
[
[
1066,
25,
1011
],
[
1011,
25,
976
]
],
[
[
1066,
64,
1184
],
[
1184,
25,
976
]
],
[
[
1066,
23,
1193
],
[
1193,
23,
1316
],
[
1316,
64,
976
]
],
[
[
1066,
23,
1461
],
[
1461,
24,
1479
],
[
1479,
24,
976
]
]
] | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tofacitinib"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tofacitinib"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
],
[
"Brexucabtagene autoleucel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Durvalumab"
],
[
"Durvalumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
]
] | Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Natalizumab may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel and Brexucabtagene autoleucel may lead to a major life threatening interaction when taken with Tofacitinib
Natalizumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Tofacitinib
Natalizumab may lead to a major life threatening interaction when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Tofacitinib
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Durvalumab and Durvalumab may lead to a major life threatening interaction when taken with Tofacitinib
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib |
DB08880 | DB14731 | 1,510 | 1,518 | [
"DDInter1771",
"DDInter1741"
] | Teriflunomide | Tagraxofusp | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide. | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is a myeloid malignancy in the dendritic cell lineage. It was also approved by the European Commission on January 7, 2021. | Major | 2 | [
[
[
1510,
25,
1518
]
],
[
[
1510,
64,
1324
],
[
1324,
24,
1518
]
],
[
[
1510,
63,
170
],
[
170,
24,
1518
]
],
[
[
1510,
25,
1613
],
[
1613,
24,
1518
]
],
[
[
1510,
24,
242
],
[
242,
63,
1518
]
],
[
[
1510,
24,
1450
],
[
1450,
24,
1518
]
],
[
[
1510,
64,
1070
],
[
1070,
25,
1518
]
],
[
[
1510,
64,
1324
],
[
1324,
63,
176
],
[
176,
24,
1518
]
],
[
[
1510,
63,
170
],
[
170,
63,
176
],
[
176,
24,
1518
]
],
[
[
1510,
64,
1647
],
[
1647,
24,
372
],
[
372,
24,
1518
]
]
] | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
],
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
]
] | Teriflunomide may lead to a major life threatening interaction when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Teriflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Teriflunomide may lead to a major life threatening interaction when taken with Mipomersen and Mipomersen may lead to a major life threatening interaction when taken with Tagraxofusp
Teriflunomide may lead to a major life threatening interaction when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Teriflunomide may lead to a major life threatening interaction when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp |
DB00795 | DB01357 | 50 | 890 | [
"DDInter1725",
"DDInter1160"
] | Sulfasalazine | Mestranol | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulf | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Moderate | 1 | [
[
[
50,
24,
890
]
],
[
[
50,
63,
1438
],
[
1438,
1,
890
]
],
[
[
50,
18,
5415
],
[
5415,
46,
890
]
],
[
[
50,
63,
91
],
[
91,
24,
890
]
],
[
[
50,
24,
416
],
[
416,
24,
890
]
],
[
[
50,
64,
126
],
[
126,
24,
890
]
],
[
[
50,
24,
1033
],
[
1033,
63,
890
]
],
[
[
50,
24,
1096
],
[
1096,
25,
890
]
],
[
[
50,
63,
1438
],
[
1438,
1,
1417
],
[
1417,
40,
890
]
],
[
[
50,
18,
5415
],
[
5415,
46,
1495
],
[
1495,
1,
890
]
]
] | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
[
"Estradiol",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) downregulates {v} (Gene)",
"UBQLN2"
],
[
"UBQLN2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mestranol"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
],
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mestranol"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
[
"Estradiol",
"{u} (Compound) resembles {v} (Compound)",
"Estramustine"
],
[
"Estramustine",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) downregulates {v} (Gene)",
"UBQLN2"
],
[
"UBQLN2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ethinylestradiol"
],
[
"Ethinylestradiol",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
]
]
] | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol (Compound) resembles Mestranol (Compound)
Sulfasalazine (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Mestranol (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Mestranol
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Mestranol
Sulfasalazine may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Mestranol
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Mestranol
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may lead to a major life threatening interaction when taken with Mestranol
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol (Compound) resembles Estramustine (Compound) and Estramustine (Compound) resembles Mestranol (Compound)
Sulfasalazine (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ethinylestradiol (Compound) and Ethinylestradiol (Compound) resembles Mestranol (Compound) |
DB00059 | DB01222 | 1,560 | 617 | [
"DDInter1404",
"DDInter246"
] | Pegaspargase | Budesonide | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with [formoterol]. | Moderate | 1 | [
[
[
1560,
24,
617
]
],
[
[
1560,
24,
251
],
[
251,
1,
617
]
],
[
[
1560,
24,
1439
],
[
1439,
63,
617
]
],
[
[
1560,
24,
139
],
[
139,
24,
617
]
],
[
[
1560,
25,
1137
],
[
1137,
63,
617
]
],
[
[
1560,
63,
1648
],
[
1648,
24,
617
]
],
[
[
1560,
24,
851
],
[
851,
25,
617
]
],
[
[
1560,
25,
375
],
[
375,
64,
617
]
],
[
[
1560,
24,
384
],
[
384,
64,
617
]
],
[
[
1560,
25,
581
],
[
581,
25,
617
]
]
] | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
],
[
"Measles virus vaccine live attenuated",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
]
]
] | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Pegaspargase may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone may lead to a major life threatening interaction when taken with Budesonide
Pegaspargase may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Budesonide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Budesonide
Pegaspargase may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Budesonide |
DB01068 | DB08865 | 1,565 | 1,593 | [
"DDInter411",
"DDInter448"
] | Clonazepam | Crizotinib | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released for sale from Roche in the US in 1975,[T469,T472] clonazepam has experienced a storied history in the treatment of the aforementioned medical conditions. Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. Unfortunately | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Moderate | 1 | [
[
[
1565,
24,
1593
]
],
[
[
1565,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1565,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
1565,
24,
283
],
[
283,
62,
1593
]
],
[
[
1565,
1,
1418
],
[
1418,
24,
1593
]
],
[
[
1565,
23,
286
],
[
286,
63,
1593
]
],
[
[
1565,
24,
375
],
[
375,
63,
1593
]
],
[
[
1565,
63,
1057
],
[
1057,
24,
1593
]
],
[
[
1565,
40,
523
],
[
523,
24,
1593
]
],
[
[
1565,
24,
593
],
[
593,
24,
1593
]
]
] | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Clonazepam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Clonazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Estazolam"
],
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Clonazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
],
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
]
] | Clonazepam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Clonazepam (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Clonazepam (Compound) resembles Estazolam (Compound) and Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Clonazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Clonazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib |
DB00794 | DB09074 | 759 | 1,362 | [
"DDInter1521",
"DDInter1327"
] | Primidone | Olaparib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016. | Major | 2 | [
[
[
759,
25,
1362
]
],
[
[
759,
63,
896
],
[
896,
24,
1362
]
],
[
[
759,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
759,
25,
1478
],
[
1478,
24,
1362
]
],
[
[
759,
64,
168
],
[
168,
24,
1362
]
],
[
[
759,
24,
1619
],
[
1619,
63,
1362
]
],
[
[
759,
25,
214
],
[
214,
63,
1362
]
],
[
[
759,
62,
752
],
[
752,
24,
1362
]
],
[
[
759,
40,
362
],
[
362,
25,
1362
]
],
[
[
759,
25,
760
],
[
760,
25,
1362
]
]
] | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Primidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Phenytoin"
],
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
]
] | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Primidone may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Primidone may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Primidone may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Primidone may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Primidone (Compound) resembles Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Olaparib
Primidone may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Olaparib |
DB01281 | DB10276 | 881 | 1,624 | [
"DDInter5",
"DDInter1623"
] | Abatacept | Rotavirus vaccine | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077). | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotarix is a live attenuated vaccine containing the 89-12 human strain.[Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection. | Major | 2 | [
[
[
881,
25,
1624
]
],
[
[
881,
25,
1583
],
[
1583,
64,
1624
]
],
[
[
881,
25,
375
],
[
375,
25,
1624
]
],
[
[
881,
63,
58
],
[
58,
25,
1624
]
],
[
[
881,
24,
270
],
[
270,
64,
1624
]
],
[
[
881,
24,
259
],
[
259,
25,
1624
]
],
[
[
881,
64,
581
],
[
581,
25,
1624
]
],
[
[
881,
25,
1583
],
[
1583,
63,
322
],
[
322,
25,
1624
]
],
[
[
881,
25,
375
],
[
375,
64,
617
],
[
617,
24,
1624
]
],
[
[
881,
63,
58
],
[
58,
24,
617
],
[
617,
24,
1624
]
]
] | [
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rotavirus vaccine"
]
]
] | Abatacept may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may lead to a major life threatening interaction when taken with Rotavirus vaccine
Abatacept may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Rotavirus vaccine
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may lead to a major life threatening interaction when taken with Rotavirus vaccine
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Rotavirus vaccine
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may lead to a major life threatening interaction when taken with Rotavirus vaccine
Abatacept may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Rotavirus vaccine
Abatacept may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Rotavirus vaccine
Abatacept may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine |
DB00283 | DB01242 | 701 | 1,237 | [
"DDInter395",
"DDInter410"
] | Clemastine | Clomipramine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine. | Moderate | 1 | [
[
[
701,
24,
1237
]
],
[
[
701,
24,
684
],
[
684,
1,
1237
]
],
[
[
701,
24,
902
],
[
902,
40,
1237
]
],
[
[
701,
24,
272
],
[
272,
24,
1237
]
],
[
[
701,
24,
649
],
[
649,
63,
1237
]
],
[
[
701,
6,
12523
],
[
12523,
45,
1237
]
],
[
[
701,
21,
29164
],
[
29164,
60,
1237
]
],
[
[
701,
35,
1511
],
[
1511,
63,
1237
]
],
[
[
701,
63,
352
],
[
352,
24,
1237
]
],
[
[
701,
35,
1594
],
[
1594,
24,
1237
]
]
] | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
"Clobazam",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Clemastine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Clomipramine"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Photosensitivity"
],
[
"Photosensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clomipramine"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
]
] | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Clomipramine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Clemastine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Clomipramine (Compound)
Clemastine (Compound) causes Photosensitivity (Side Effect) and Photosensitivity (Side Effect) is caused by Clomipramine (Compound)
Clemastine (Compound) resembles Mepenzolate (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine |
DB00501 | DB01409 | 752 | 1,415 | [
"DDInter380",
"DDInter1815"
] | Cimetidine | Tiotropium | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium]. Tiotropium was granted FDA approval on 30 January 2004. | Minor | 0 | [
[
[
752,
23,
1415
]
],
[
[
752,
6,
8374
],
[
8374,
45,
1415
]
],
[
[
752,
21,
28996
],
[
28996,
60,
1415
]
],
[
[
752,
24,
1237
],
[
1237,
24,
1415
]
],
[
[
752,
23,
1664
],
[
1664,
24,
1415
]
],
[
[
752,
63,
194
],
[
194,
24,
1415
]
],
[
[
752,
24,
573
],
[
573,
63,
1415
]
],
[
[
752,
25,
684
],
[
684,
24,
1415
]
],
[
[
752,
62,
216
],
[
216,
24,
1415
]
],
[
[
752,
6,
8374
],
[
8374,
45,
1405
],
[
1405,
24,
1415
]
]
] | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tiotropium"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Tiotropium"
]
],
[
[
"Cimetidine",
"{u} (Compound) causes {v} (Side Effect)",
"Musculoskeletal discomfort"
],
[
"Musculoskeletal discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tiotropium"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
],
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
],
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
]
] | Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tiotropium (Compound)
Cimetidine (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Tiotropium (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine and Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Cimetidine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cyclobenzaprine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium |
DB00047 | DB08907 | 176 | 1,344 | [
"DDInter932",
"DDInter280"
] | Insulin glargine | Canagliflozin | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis. Insulin is an important treatment in the management of Type 1 Diabetes (T1D), which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients . | Moderate | 1 | [
[
[
176,
24,
1344
]
],
[
[
176,
24,
549
],
[
549,
1,
1344
]
],
[
[
176,
23,
1103
],
[
1103,
23,
1344
]
],
[
[
176,
24,
1033
],
[
1033,
63,
1344
]
],
[
[
176,
25,
739
],
[
739,
24,
1344
]
],
[
[
176,
24,
1486
],
[
1486,
24,
1344
]
],
[
[
176,
63,
818
],
[
818,
24,
1344
]
],
[
[
176,
23,
274
],
[
274,
24,
1344
]
],
[
[
176,
25,
255
],
[
255,
63,
1344
]
],
[
[
176,
25,
246
],
[
246,
25,
1344
]
]
] | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Insulin glargine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Canagliflozin"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Insulin glargine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyrotropin alfa"
],
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Insulin glargine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phentolamine"
],
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Insulin glargine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Insulin glargine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canagliflozin"
]
]
] | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Canagliflozin
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Insulin glargine may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Thyrotropin alfa and Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Phentolamine and Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Insulin glargine may lead to a major life threatening interaction when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Insulin glargine may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Canagliflozin |
DB00204 | DB09134 | 228 | 1,552 | [
"DDInter580",
"DDInter966"
] | Dofetilide | Ioversol | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol, enhances the contrast between vessels in the path of the flow of the contrast medium and normal tissue, allowing the visualization of internal structures. Ioversol is a highly hydrophilic agent considered to be generally safe; however, serious adverse reactions have been reported due to the inadvertent intrathecal administration of ioversol, which is only indicated for intra-arterial and intravenous use. Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left ventriculography.[L41780,L41790] | Moderate | 1 | [
[
[
228,
24,
1552
]
],
[
[
228,
25,
589
],
[
589,
25,
1552
]
],
[
[
228,
24,
629
],
[
629,
25,
1552
]
],
[
[
228,
25,
589
],
[
589,
25,
33
],
[
33,
24,
1552
]
],
[
[
228,
24,
629
],
[
629,
24,
33
],
[
33,
24,
1552
]
],
[
[
228,
40,
540
],
[
540,
1,
33
],
[
33,
24,
1552
]
],
[
[
228,
25,
589
],
[
589,
64,
1648
],
[
1648,
24,
1552
]
],
[
[
228,
24,
629
],
[
629,
63,
494
],
[
494,
24,
1552
]
],
[
[
228,
25,
1287
],
[
1287,
24,
1605
],
[
1605,
24,
1552
]
],
[
[
228,
6,
8374
],
[
8374,
45,
33
],
[
33,
24,
1552
]
]
] | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Dofetilide",
"{u} (Compound) resembles {v} (Compound)",
"Dronedarone"
],
[
"Dronedarone",
"{u} (Compound) resembles {v} (Compound)",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
]
] | Dofetilide may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Ioversol
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Ioversol
Dofetilide may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Dofetilide (Compound) resembles Dronedarone (Compound) and Dronedarone (Compound) resembles Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Dofetilide may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Dofetilide may lead to a major life threatening interaction when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ioversol |
DB00073 | DB08868 | 1,394 | 1,011 | [
"DDInter1608",
"DDInter737"
] | Rituximab | Fingolimod | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences, [FDA label]. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL), however, has now been approved for a variety of conditions [FDA label]. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab). | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Major | 2 | [
[
[
1394,
25,
1011
]
],
[
[
1394,
24,
748
],
[
748,
63,
1011
]
],
[
[
1394,
24,
1136
],
[
1136,
24,
1011
]
],
[
[
1394,
25,
976
],
[
976,
64,
1011
]
],
[
[
1394,
25,
1066
],
[
1066,
25,
1011
]
],
[
[
1394,
24,
259
],
[
259,
25,
1011
]
],
[
[
1394,
24,
1362
],
[
1362,
64,
1011
]
],
[
[
1394,
64,
1057
],
[
1057,
25,
1011
]
],
[
[
1394,
63,
1184
],
[
1184,
25,
1011
]
],
[
[
1394,
24,
748
],
[
748,
63,
976
],
[
976,
64,
1011
]
]
] | [
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
],
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
],
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
]
] | Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Rituximab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Fingolimod
Rituximab may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Fingolimod
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may lead to a major life threatening interaction when taken with Fingolimod
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Fingolimod
Rituximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Fingolimod
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Fingolimod
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Fingolimod |
DB00367 | DB08820 | 566 | 1,478 | [
"DDInter1061",
"DDInter997"
] | Levonorgestrel | Ivacaftor | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of these devices are known as Jaydess, Kyleena, and Mirena. A subdermal implant of levonorgestrel that slowly releases the hormone over a long-term period is also available. In addition to the above uses, levonorgestrel is used as a component of long-term combination contraceptives.[A181991,L7760,L7778] Globally, levonorgestrel is the most commonly used emergency contraceptive. It was initially granted FDA approval in 1982 and was the first emergency contraceptive containing only progesterone, showing high levels of efficacy and a lack of estrogen | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms. | Moderate | 1 | [
[
[
566,
24,
1478
]
],
[
[
566,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
566,
21,
29221
],
[
29221,
60,
1478
]
],
[
[
566,
1,
1336
],
[
1336,
24,
1478
]
],
[
[
566,
24,
1411
],
[
1411,
24,
1478
]
],
[
[
566,
63,
245
],
[
245,
24,
1478
]
],
[
[
566,
24,
1362
],
[
1362,
63,
1478
]
],
[
[
566,
25,
1040
],
[
1040,
63,
1478
]
],
[
[
566,
23,
578
],
[
578,
24,
1478
]
],
[
[
566,
40,
167
],
[
167,
24,
1478
]
]
] | [
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ivacaftor"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation"
],
[
"Infestation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ivacaftor"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) resembles {v} (Compound)",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Levonorgestrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Levonorgestrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
]
] | Levonorgestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Levonorgestrel (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Levonorgestrel (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Levonorgestrel may lead to a major life threatening interaction when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Levonorgestrel may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Levonorgestrel (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor |
DB01320 | DB12941 | 651 | 466 | [
"DDInter783",
"DDInter481"
] | Fosphenytoin | Darolutamide | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019. | Major | 2 | [
[
[
651,
25,
466
]
],
[
[
651,
25,
1374
],
[
1374,
23,
466
]
],
[
[
651,
64,
600
],
[
600,
23,
466
]
],
[
[
651,
63,
86
],
[
86,
23,
466
]
],
[
[
651,
25,
159
],
[
159,
62,
466
]
],
[
[
651,
24,
738
],
[
738,
24,
466
]
],
[
[
651,
63,
392
],
[
392,
24,
466
]
],
[
[
651,
25,
792
],
[
792,
24,
466
]
],
[
[
651,
40,
307
],
[
307,
24,
466
]
],
[
[
651,
64,
1419
],
[
1419,
24,
466
]
]
] | [
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
]
] | Fosphenytoin may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fosphenytoin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fosphenytoin may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Fosphenytoin may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Fosphenytoin (Compound) resembles Modafinil (Compound) and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Fosphenytoin may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide |
DB00960 | DB06723 | 887 | 115 | [
"DDInter1471",
"DDInter58"
] | Pindolol | Aluminum hydroxide | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s. Pindolol was granted FDA approval on 3 September 1982. | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Minor | 0 | [
[
[
887,
23,
115
]
],
[
[
887,
21,
28845
],
[
28845,
60,
115
]
],
[
[
887,
63,
870
],
[
870,
23,
115
]
],
[
[
887,
1,
88
],
[
88,
23,
115
]
],
[
[
887,
24,
401
],
[
401,
23,
115
]
],
[
[
887,
40,
1121
],
[
1121,
23,
115
]
],
[
[
887,
24,
478
],
[
478,
24,
115
]
],
[
[
887,
62,
417
],
[
417,
24,
115
]
],
[
[
887,
63,
1123
],
[
1123,
24,
115
]
],
[
[
887,
24,
636
],
[
636,
64,
115
]
]
] | [
[
[
"Pindolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Pindolol",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aluminum hydroxide"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Bisoprolol"
],
[
"Bisoprolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Pindolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
],
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
],
[
"Calcium citrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aluminum hydroxide"
]
]
] | Pindolol (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Aluminum hydroxide (Compound)
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Pindolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Pindolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Pindolol may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate and Calcium citrate may lead to a major life threatening interaction when taken with Aluminum hydroxide |
DB04896 | DB06209 | 901 | 256 | [
"DDInter1220",
"DDInter1508"
] | Milnacipran | Prasugrel | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia, although other regional regulatory authorities like the EMA, among others, have not yet approved the agent for such treatment, citing lack of robust evidence of efficacy, insufficient demonstration of maintenance of effect, and other concerns [F3928, F3934]. Nevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference for noradrenaline reuptake inhibition - which is potentially a point of interest given the plausible | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009. | Moderate | 1 | [
[
[
901,
24,
256
]
],
[
[
901,
21,
28681
],
[
28681,
60,
256
]
],
[
[
901,
64,
593
],
[
593,
23,
256
]
],
[
[
901,
63,
305
],
[
305,
24,
256
]
],
[
[
901,
40,
41
],
[
41,
63,
256
]
],
[
[
901,
24,
578
],
[
578,
63,
256
]
],
[
[
901,
64,
121
],
[
121,
24,
256
]
],
[
[
901,
1,
1349
],
[
1349,
24,
256
]
],
[
[
901,
63,
1317
],
[
1317,
25,
256
]
],
[
[
901,
24,
365
],
[
365,
64,
256
]
]
] | [
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Milnacipran",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Prasugrel"
]
],
[
[
"Milnacipran",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Milnacipran",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Meperidine"
],
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
],
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
],
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
]
] | Milnacipran (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Milnacipran may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Milnacipran (Compound) resembles Levomilnacipran (Compound) and Levo
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Milnacipran may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Milnacipran (Compound) resembles Meperidine (Compound) and Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may lead to a major life threatening interaction when taken with Prasugrel
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin and Dalteparin may lead to a major life threatening interaction when taken with Prasugrel |
DB00661 | DB08875 | 122 | 1,618 | [
"DDInter1928",
"DDInter262"
] | Verapamil | Cabozantinib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] | Moderate | 1 | [
[
[
122,
24,
1618
]
],
[
[
122,
25,
1135
],
[
1135,
62,
1618
]
],
[
[
122,
24,
723
],
[
723,
24,
1618
]
],
[
[
122,
24,
384
],
[
384,
63,
1618
]
],
[
[
122,
25,
1476
],
[
1476,
63,
1618
]
],
[
[
122,
63,
1195
],
[
1195,
24,
1618
]
],
[
[
122,
25,
543
],
[
543,
24,
1618
]
],
[
[
122,
23,
283
],
[
283,
63,
1618
]
],
[
[
122,
23,
222
],
[
222,
24,
1618
]
],
[
[
122,
62,
1101
],
[
1101,
24,
1618
]
]
] | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabozantinib"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
]
] | Verapamil may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Verapamil may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Verapamil may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Verapamil may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Verapamil may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Verapamil may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib |
DB00366 | DB00418 | 1,594 | 536 | [
"DDInter600",
"DDInter1650"
] | Doxylamine | Secobarbital | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Moderate | 1 | [
[
[
1594,
24,
536
]
],
[
[
1594,
63,
1023
],
[
1023,
1,
536
]
],
[
[
1594,
24,
697
],
[
697,
1,
536
]
],
[
[
1594,
24,
682
],
[
682,
40,
536
]
],
[
[
1594,
21,
28769
],
[
28769,
60,
536
]
],
[
[
1594,
24,
1233
],
[
1233,
63,
536
]
],
[
[
1594,
24,
999
],
[
999,
24,
536
]
],
[
[
1594,
35,
272
],
[
272,
63,
536
]
],
[
[
1594,
63,
1648
],
[
1648,
24,
536
]
],
[
[
1594,
25,
1629
],
[
1629,
63,
536
]
]
] | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiopental"
],
[
"Thiopental",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Secobarbital"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
],
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
]
],
[
[
"Doxylamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
]
]
] | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Secobarbital (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Secobarbital (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Thiopental and Thiopental (Compound) resembles Secobarbital (Compound)
Doxylamine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Secobarbital (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Doxylamine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital |
DB08916 | DB11796 | 26 | 1,612 | [
"DDInter32",
"DDInter786"
] | Afatinib | Fostemsavir | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim. | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the HIV-1 viral lifecycle. The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically orthogonal therapies) for the treatment of HIV-1 patients with resistant infections. Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant HIV-1 infection whom are failing their current therapy.[L14867,L14917] Targeting gp120 subunits is a new and novel therapeutic approach to HIV-1 infection, and the addition of attachment inhibitors, like temsavir, to the armament of therapies targeted against HIV-1 fills a necessary niche for therapeutic options in patients left with few, if any, viable treatments. | Moderate | 1 | [
[
[
26,
24,
1612
]
],
[
[
26,
24,
1476
],
[
1476,
62,
1612
]
],
[
[
26,
63,
1220
],
[
1220,
23,
1612
]
],
[
[
26,
63,
1424
],
[
1424,
24,
1612
]
],
[
[
26,
24,
1033
],
[
1033,
63,
1612
]
],
[
[
26,
64,
1510
],
[
1510,
24,
1612
]
],
[
[
26,
24,
927
],
[
927,
24,
1612
]
],
[
[
26,
24,
351
],
[
351,
25,
1612
]
],
[
[
26,
24,
913
],
[
913,
64,
1612
]
],
[
[
26,
63,
478
],
[
478,
25,
1612
]
]
] | [
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Afatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
]
]
] | Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Afatinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Fostemsavir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Fostemsavir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Fostemsavir |
DB00208 | DB00501 | 1,018 | 752 | [
"DDInter1804",
"DDInter380"
] | Ticlopidine | Cimetidine | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine. | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Moderate | 1 | [
[
[
1018,
24,
752
]
],
[
[
1018,
6,
7950
],
[
7950,
45,
752
]
],
[
[
1018,
21,
29134
],
[
29134,
60,
752
]
],
[
[
1018,
24,
935
],
[
935,
62,
752
]
],
[
[
1018,
24,
831
],
[
831,
23,
752
]
],
[
[
1018,
25,
256
],
[
256,
62,
752
]
],
[
[
1018,
23,
1384
],
[
1384,
62,
752
]
],
[
[
1018,
23,
1252
],
[
1252,
23,
752
]
],
[
[
1018,
25,
792
],
[
792,
63,
752
]
],
[
[
1018,
24,
109
],
[
109,
24,
752
]
]
] | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetidine"
]
],
[
[
"Ticlopidine",
"{u} (Compound) causes {v} (Side Effect)",
"Flatulence"
],
[
"Flatulence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cimetidine"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
],
[
"Magaldrate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
]
] | Ticlopidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Cimetidine (Compound)
Ticlopidine (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Cimetidine (Compound)
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Ticlopidine may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Ticlopidine may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine |
DB01267 | DB06176 | 519 | 1,342 | [
"DDInter1381",
"DDInter1616"
] | Paliperidone | Romidepsin | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749] | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
519,
24,
1342
]
],
[
[
519,
62,
112
],
[
112,
23,
1342
]
],
[
[
519,
63,
485
],
[
485,
24,
1342
]
],
[
[
519,
24,
1616
],
[
1616,
63,
1342
]
],
[
[
519,
40,
1664
],
[
1664,
24,
1342
]
],
[
[
519,
24,
1151
],
[
1151,
24,
1342
]
],
[
[
519,
64,
1493
],
[
1493,
25,
1342
]
],
[
[
519,
25,
985
],
[
985,
64,
1342
]
],
[
[
519,
25,
1069
],
[
1069,
25,
1342
]
],
[
[
519,
40,
924
],
[
924,
25,
1342
]
]
] | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Paliperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Romidepsin"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Paliperidone",
"{u} (Compound) resembles {v} (Compound)",
"Risperidone"
],
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Paliperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Paliperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Paliperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Paliperidone",
"{u} (Compound) resembles {v} (Compound)",
"Iloperidone"
],
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
]
] | Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Paliperidone (Compound) resembles Risperidone (Compound) and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Paliperidone may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Romidepsin
Paliperidone may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Romidepsin
Paliperidone may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Romidepsin
Paliperidone (Compound) resembles Iloperidone (Compound) and Iloperidone may lead to a major life threatening interaction when taken with Romidepsin |
DB00845 | DB01169 | 1,490 | 57 | [
"DDInter406",
"DDInter120"
] | Clofazimine | Arsenic trioxide | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis treatments such as [rifampicin] and [isoniazid]. | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide. | Major | 2 | [
[
[
1490,
25,
57
]
],
[
[
1490,
6,
8374
],
[
8374,
45,
57
]
],
[
[
1490,
23,
112
],
[
112,
23,
57
]
],
[
[
1490,
24,
603
],
[
603,
63,
57
]
],
[
[
1490,
24,
480
],
[
480,
24,
57
]
],
[
[
1490,
63,
543
],
[
543,
24,
57
]
],
[
[
1490,
24,
1616
],
[
1616,
64,
57
]
],
[
[
1490,
25,
1154
],
[
1154,
64,
57
]
],
[
[
1490,
63,
485
],
[
485,
25,
57
]
],
[
[
1490,
64,
1425
],
[
1425,
25,
57
]
]
] | [
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Clofazimine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Arsenic trioxide"
]
],
[
[
"Clofazimine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
]
] | Clofazimine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may lead to a major life threatening interaction when taken with Arsenic trioxide
Clofazimine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Arsenic trioxide
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Arsenic trioxide
Clofazimine may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Arsenic trioxide |
DB00738 | DB11642 | 485 | 938 | [
"DDInter1420",
"DDInter1480"
] | Pentamidine | Pitolisant | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pitolisant was comparable to that of [modafinil]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms ; however, the safety of use in adolescent or paediatric patients have not been established with pitolisant. Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 for the treatment of narcolepsy with or without cataplexy. FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults. | Moderate | 1 | [
[
[
485,
24,
938
]
],
[
[
485,
23,
112
],
[
112,
23,
938
]
],
[
[
485,
24,
28
],
[
28,
24,
938
]
],
[
[
485,
63,
600
],
[
600,
24,
938
]
],
[
[
485,
24,
927
],
[
927,
63,
938
]
],
[
[
485,
25,
1154
],
[
1154,
25,
938
]
],
[
[
485,
25,
351
],
[
351,
64,
938
]
],
[
[
485,
64,
1425
],
[
1425,
25,
938
]
],
[
[
485,
24,
913
],
[
913,
64,
938
]
],
[
[
485,
24,
129
],
[
129,
25,
938
]
]
] | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Pentamidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pitolisant"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
]
] | Pentamidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Pentamidine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Pitolisant
Pentamidine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Pitolisant
Pentamidine may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Pitolisant
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Pitolisant
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Pitolisant |
DB00208 | DB06700 | 1,018 | 643 | [
"DDInter1804",
"DDInter511"
] | Ticlopidine | Desvenlafaxine | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine. | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. Although the exact mechanism of pathophysiology is still unknown, imbalances or deficiencies of monoamines have been heavily implicated, thus the rationale behind the use of SNRI to treat MDD. Desvenlafaxine has a very similar pharmacological, efficacy, and safety profile as [venlafaxine]. The major difference is the potential for drug interaction since venlafaxine is mainly metabolized by CYP2D6 while desvenlafaxine is conjugated by UGT; therefore, desvenlafaxine is less likely to cause drug-drug interaction when taken with medications affecting the CYP2D6 pathway. | Moderate | 1 | [
[
[
1018,
24,
643
]
],
[
[
1018,
24,
1100
],
[
1100,
1,
643
]
],
[
[
1018,
6,
8374
],
[
8374,
45,
643
]
],
[
[
1018,
21,
28709
],
[
28709,
60,
643
]
],
[
[
1018,
24,
752
],
[
752,
23,
643
]
],
[
[
1018,
25,
292
],
[
292,
63,
643
]
],
[
[
1018,
24,
1274
],
[
1274,
24,
643
]
],
[
[
1018,
25,
1047
],
[
1047,
24,
643
]
],
[
[
1018,
63,
25
],
[
25,
24,
643
]
],
[
[
1018,
64,
834
],
[
834,
24,
643
]
]
] | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Desvenlafaxine"
]
],
[
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Desvenlafaxine"
]
],
[
[
"Ticlopidine",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Desvenlafaxine"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
],
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
]
] | Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Ticlopidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Desvenlafaxine (Compound)
Ticlopidine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Desvenlafaxine (Compound)
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Desvenlafaxine
Ticlopidine may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Ticlopidine may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Ticlopidine may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine |
DB00924 | DB09268 | 1,405 | 1,662 | [
"DDInter454",
"DDInter1464"
] | Cyclobenzaprine | Picosulfuric acid | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Moderate | 1 | [
[
[
1405,
24,
1662
]
],
[
[
1405,
40,
1164
],
[
1164,
24,
1662
]
],
[
[
1405,
24,
1619
],
[
1619,
63,
1662
]
],
[
[
1405,
24,
820
],
[
820,
24,
1662
]
],
[
[
1405,
25,
1264
],
[
1264,
24,
1662
]
],
[
[
1405,
64,
475
],
[
475,
24,
1662
]
],
[
[
1405,
63,
999
],
[
999,
24,
1662
]
],
[
[
1405,
24,
478
],
[
478,
25,
1662
]
],
[
[
1405,
40,
1164
],
[
1164,
24,
484
],
[
484,
63,
1662
]
],
[
[
1405,
24,
1619
],
[
1619,
63,
1164
],
[
1164,
24,
1662
]
]
] | [
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cyclobenzaprine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cyclobenzaprine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
]
] | Cyclobenzaprine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cyclobenzaprine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cyclobenzaprine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Picosulfuric acid
Cyclobenzaprine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid |
DB00694 | DB01267 | 51 | 519 | [
"DDInter485",
"DDInter1381"
] | Daunorubicin | Paliperidone | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749] | Moderate | 1 | [
[
[
51,
24,
519
]
],
[
[
51,
24,
1664
],
[
1664,
1,
519
]
],
[
[
51,
25,
924
],
[
924,
1,
519
]
],
[
[
51,
6,
7524
],
[
7524,
45,
519
]
],
[
[
51,
21,
28898
],
[
28898,
60,
519
]
],
[
[
51,
23,
112
],
[
112,
23,
519
]
],
[
[
51,
24,
36
],
[
36,
63,
519
]
],
[
[
51,
24,
477
],
[
477,
24,
519
]
],
[
[
51,
63,
1648
],
[
1648,
24,
519
]
],
[
[
51,
25,
770
],
[
770,
24,
519
]
]
] | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} (Compound) resembles {v} (Compound)",
"Paliperidone"
]
],
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloperidone",
"{u} (Compound) resembles {v} (Compound)",
"Paliperidone"
]
],
[
[
"Daunorubicin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Paliperidone"
]
],
[
[
"Daunorubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paliperidone"
]
],
[
[
"Daunorubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paliperidone"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
]
] | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Daunorubicin may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound)
Daunorubicin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paliperidone (Compound)
Daunorubicin (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Paliperidone (Compound)
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Paliperidone
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Daunorubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone |
DB00390 | DB08816 | 1,252 | 578 | [
"DDInter554",
"DDInter1802"
] | Digoxin | Ticagrelor | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Moderate | 1 | [
[
[
1252,
24,
578
]
],
[
[
1252,
10,
11576
],
[
11576,
44,
578
]
],
[
[
1252,
6,
4973
],
[
4973,
45,
578
]
],
[
[
1252,
21,
28762
],
[
28762,
60,
578
]
],
[
[
1252,
25,
1011
],
[
1011,
62,
578
]
],
[
[
1252,
24,
868
],
[
868,
63,
578
]
],
[
[
1252,
24,
1220
],
[
1220,
24,
578
]
],
[
[
1252,
62,
1018
],
[
1018,
24,
578
]
],
[
[
1252,
23,
885
],
[
885,
24,
578
]
],
[
[
1252,
24,
913
],
[
913,
64,
578
]
]
] | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Digoxin",
"{u} (Compound) palliates {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
"{u} (Disease) is treated by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Digoxin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Digoxin",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Digoxin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
]
]
] | Digoxin (Compound) palliates coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Ticagrelor (Compound)
Digoxin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Digoxin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Digoxin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Digoxin may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Digoxin may cause a minor interaction that can limit clinical effects when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Ticagrelor |
DB00434 | DB00496 | 13 | 194 | [
"DDInter459",
"DDInter480"
] | Cyproheptadine | Darifenacin | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments. | Moderate | 1 | [
[
[
13,
24,
194
]
],
[
[
13,
24,
704
],
[
704,
1,
194
]
],
[
[
13,
24,
1511
],
[
1511,
63,
194
]
],
[
[
13,
63,
576
],
[
576,
1,
194
]
],
[
[
13,
6,
4304
],
[
4304,
45,
194
]
],
[
[
13,
21,
28714
],
[
28714,
60,
194
]
],
[
[
13,
63,
999
],
[
999,
24,
194
]
],
[
[
13,
25,
1621
],
[
1621,
64,
194
]
],
[
[
13,
24,
262
],
[
262,
74,
194
]
],
[
[
13,
63,
352
],
[
352,
35,
194
]
]
] | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound)",
"Darifenacin"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Darifenacin"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
"Darifenacin"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Darifenacin"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
]
],
[
[
"Cyproheptadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darifenacin"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
]
]
] | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Darifenacin (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Darifenacin (Compound)
Cyproheptadine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Darifenacin (Compound)
Cyproheptadine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Darifenacin (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin
Cyproheptadine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Darifenacin
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium (Compound) resembles Darifenacin (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium (Compound) resembles Darifenacin (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin |
DB09065 | DB15091 | 760 | 676 | [
"DDInter424",
"DDInter1901"
] | Cobicistat | Upadacitinib | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Major | 2 | [
[
[
760,
25,
676
]
],
[
[
760,
63,
1249
],
[
1249,
24,
676
]
],
[
[
760,
25,
283
],
[
283,
24,
676
]
],
[
[
760,
64,
1593
],
[
1593,
24,
676
]
],
[
[
760,
62,
555
],
[
555,
24,
676
]
],
[
[
760,
24,
1580
],
[
1580,
24,
676
]
],
[
[
760,
24,
1654
],
[
1654,
63,
676
]
],
[
[
760,
25,
1339
],
[
1339,
63,
676
]
],
[
[
760,
25,
503
],
[
503,
25,
676
]
],
[
[
760,
63,
859
],
[
859,
25,
676
]
]
] | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
],
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Cobicistat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
[
"Somapacitan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
],
[
"Zanubrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
]
] | Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Cobicistat may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Cobicistat may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Netupitant and Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol and Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Cobicistat may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Cobicistat may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Upadacitinib
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole may lead to a major life threatening interaction when taken with Upadacitinib |
DB00396 | DB09098 | 989 | 98 | [
"DDInter1529",
"DDInter1700"
] | Progesterone | Somatrem | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization, as well as in other formulations to promote and support pregnancy. Please see [Medroxyprogesterone acetate], [Megestrol acetate], [Dydrogesterone] and [Hydroxyprogesterone] entries for information on various other forms of progesterone. Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin [FDA label]. Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes [Label,F389 | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
989,
24,
98
]
],
[
[
989,
1,
284
],
[
284,
24,
98
]
],
[
[
989,
24,
159
],
[
159,
63,
98
]
],
[
[
989,
24,
609
],
[
609,
24,
98
]
],
[
[
989,
63,
1647
],
[
1647,
24,
98
]
],
[
[
989,
40,
870
],
[
870,
24,
98
]
],
[
[
989,
25,
1456
],
[
1456,
63,
98
]
],
[
[
989,
63,
1101
],
[
1101,
25,
98
]
],
[
[
989,
1,
284
],
[
284,
24,
159
],
[
159,
63,
98
]
],
[
[
989,
24,
159
],
[
159,
63,
608
],
[
608,
23,
98
]
]
] | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Finasteride"
],
[
"Finasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Finasteride"
],
[
"Finasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
]
] | Progesterone (Compound) resembles Finasteride (Compound) and Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somatrem
Progesterone (Compound) resembles Finasteride (Compound) and Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem |
DB00286 | DB01276 | 380 | 123 | [
"DDInter439",
"DDInter706"
] | Conjugated estrogens | Exenatide | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.[L5605, T475] The conjugated estrogen product contains a mix of estrogen from which about 50% is represented by estrone sulfate followed by 25% of equilin sulfate, 15% of 17-alpha-dehydroequilenin sulfate, 3% of equilenin sulfate, 5% of 17-alpha and 17-beta-dihydroequilenin sulfate, 2% of 17-alpha-estradiolsulfate and 3% of 17-beta-estradiolsulfate. It also presents a large number of unidentified molecules with weak estrogenic activity as well as non-human molecules when it is obtained | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available. | Moderate | 1 | [
[
[
380,
24,
123
]
],
[
[
380,
24,
708
],
[
708,
63,
123
]
],
[
[
380,
24,
1573
],
[
1573,
24,
123
]
],
[
[
380,
63,
1685
],
[
1685,
24,
123
]
],
[
[
380,
1,
35
],
[
35,
63,
123
]
],
[
[
380,
40,
1438
],
[
1438,
24,
123
]
],
[
[
380,
24,
1101
],
[
1101,
25,
123
]
],
[
[
380,
24,
708
],
[
708,
63,
217
],
[
217,
24,
123
]
],
[
[
380,
24,
1476
],
[
1476,
63,
1252
],
[
1252,
23,
123
]
],
[
[
380,
63,
1685
],
[
1685,
23,
1103
],
[
1103,
23,
123
]
]
] | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
],
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
],
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Exenatide"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesartan"
],
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
]
]
] | Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Conjugated estrogens (Compound) resembles Quinestrol (Compound) and Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Conjugated estrogens (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Exenatide
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Exenatide |
DB00327 | DB08816 | 421 | 578 | [
"DDInter890",
"DDInter1802"
] | Hydromorphone | Ticagrelor | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. Due to these modifications, it presents a very high potency and comparable side effect profile to the parent compound. Even though hydromorphone does not present a 6-hydroxyl group, it is categorized under the family of phenanthrenes and it is considered a chemical under the schedule II (medical purposes with high addiction potential). The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Moderate | 1 | [
[
[
421,
24,
578
]
],
[
[
421,
6,
8374
],
[
8374,
45,
578
]
],
[
[
421,
21,
28646
],
[
28646,
60,
578
]
],
[
[
421,
24,
1039
],
[
1039,
24,
578
]
],
[
[
421,
64,
475
],
[
475,
24,
578
]
],
[
[
421,
1,
314
],
[
314,
24,
578
]
],
[
[
421,
24,
407
],
[
407,
63,
578
]
],
[
[
421,
6,
8374
],
[
8374,
45,
336
],
[
336,
23,
578
]
],
[
[
421,
21,
28646
],
[
28646,
60,
336
],
[
336,
23,
578
]
],
[
[
421,
24,
1039
],
[
1039,
24,
271
],
[
271,
62,
578
]
]
] | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Hydromorphone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Hydromorphone",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"Unspecified disorder of skin and subcutaneous tissue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Hydromorphone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Hydromorphone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Hydromorphone",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"Unspecified disorder of skin and subcutaneous tissue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
]
] | Hydromorphone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Hydromorphone (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Hydromorphone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Hydromorphone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Hydromorphone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Hydromorphone (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ticagrelor |
DB01166 | DB09330 | 477 | 985 | [
"DDInter379",
"DDInter1352"
] | Cilostazol | Osimertinib | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931] | Major | 2 | [
[
[
477,
25,
985
]
],
[
[
477,
63,
168
],
[
168,
23,
985
]
],
[
[
477,
62,
1247
],
[
1247,
23,
985
]
],
[
[
477,
24,
1478
],
[
1478,
24,
985
]
],
[
[
477,
63,
480
],
[
480,
24,
985
]
],
[
[
477,
24,
657
],
[
657,
63,
985
]
],
[
[
477,
25,
283
],
[
283,
63,
985
]
],
[
[
477,
64,
529
],
[
529,
24,
985
]
],
[
[
477,
25,
1580
],
[
1580,
24,
985
]
],
[
[
477,
35,
673
],
[
673,
24,
985
]
]
] | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Cilostazol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
]
] | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Cilostazol may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Cilostazol may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Cilostazol may lead to a major life threatening interaction when taken with Stiripentol and Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Cilostazol (Compound) resembles Aripiprazole (Compound) and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib |
DB00344 | DB00916 | 1,302 | 112 | [
"DDInter1543",
"DDInter1202"
] | Protriptyline | Metronidazole | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, alpha<sub>1</sub | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections. | Minor | 0 | [
[
[
1302,
23,
112
]
],
[
[
1302,
21,
28757
],
[
28757,
60,
112
]
],
[
[
1302,
40,
847
],
[
847,
23,
112
]
],
[
[
1302,
63,
618
],
[
618,
23,
112
]
],
[
[
1302,
24,
51
],
[
51,
23,
112
]
],
[
[
1302,
25,
11
],
[
11,
23,
112
]
],
[
[
1302,
24,
1616
],
[
1616,
62,
112
]
],
[
[
1302,
25,
1154
],
[
1154,
62,
112
]
],
[
[
1302,
64,
702
],
[
702,
23,
112
]
],
[
[
1302,
40,
413
],
[
413,
62,
112
]
]
] | [
[
[
"Protriptyline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Protriptyline",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metronidazole"
]
],
[
[
"Protriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Protriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Maprotiline"
],
[
"Maprotiline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
]
] | Protriptyline (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Metronidazole (Compound)
Protriptyline (Compound) resembles Atomoxetine (Compound) and Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Protriptyline may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Protriptyline may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Protriptyline may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Protriptyline (Compound) resembles Maprotiline (Compound) and Maprotiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole |
DB00467 | DB00731 | 1,467 | 1,144 | [
"DDInter644",
"DDInter1269"
] | Enoxacin | Nateglinide | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound. | Major | 2 | [
[
[
1467,
25,
1144
]
],
[
[
1467,
24,
1021
],
[
1021,
63,
1144
]
],
[
[
1467,
25,
870
],
[
870,
24,
1144
]
],
[
[
1467,
25,
167
],
[
167,
63,
1144
]
],
[
[
1467,
23,
450
],
[
450,
24,
1144
]
],
[
[
1467,
24,
1512
],
[
1512,
24,
1144
]
],
[
[
1467,
64,
245
],
[
245,
24,
1144
]
],
[
[
1467,
63,
417
],
[
417,
24,
1144
]
],
[
[
1467,
23,
1532
],
[
1532,
63,
1144
]
],
[
[
1467,
40,
1299
],
[
1299,
25,
1144
]
]
] | [
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nateglinide"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
],
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nateglinide"
]
]
] | Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Enoxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Enoxacin may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Enoxacin may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Enoxacin may lead to a major life threatening interaction when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Enoxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Enoxacin (Compound) resembles Trovafloxacin (Compound) and Trovafloxacin may lead to a major life threatening interaction when taken with Nateglinide |
DB00420 | DB00771 | 508 | 262 | [
"DDInter1532",
"DDInter397"
] | Promazine | Clidinium | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. | Moderate | 1 | [
[
[
508,
24,
262
]
],
[
[
508,
24,
1511
],
[
1511,
63,
262
]
],
[
[
508,
6,
2720
],
[
2720,
45,
262
]
],
[
[
508,
24,
19
],
[
19,
24,
262
]
],
[
[
508,
1,
820
],
[
820,
63,
262
]
],
[
[
508,
25,
1311
],
[
1311,
63,
262
]
],
[
[
508,
63,
701
],
[
701,
24,
262
]
],
[
[
508,
64,
475
],
[
475,
24,
262
]
],
[
[
508,
35,
401
],
[
401,
63,
262
]
],
[
[
508,
40,
21
],
[
21,
24,
262
]
]
] | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Promazine",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Compound)",
"Clidinium"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Promazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Promazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
]
] | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Promazine (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Clidinium (Compound)
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Promazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Promazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Promazine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Promazine (Compound) resembles Promethazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Promazine (Compound) resembles Amitriptyline (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Clidinium |
DB00008 | DB09074 | 491 | 1,362 | [
"DDInter1407",
"DDInter1327"
] | Peginterferon alfa-2a | Olaparib | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016. | Moderate | 1 | [
[
[
491,
24,
1362
]
],
[
[
491,
24,
896
],
[
896,
24,
1362
]
],
[
[
491,
23,
576
],
[
576,
24,
1362
]
],
[
[
491,
24,
1060
],
[
1060,
63,
1362
]
],
[
[
491,
25,
990
],
[
990,
24,
1362
]
],
[
[
491,
25,
1066
],
[
1066,
25,
1362
]
],
[
[
491,
24,
655
],
[
655,
25,
1362
]
],
[
[
491,
25,
676
],
[
676,
64,
1362
]
],
[
[
491,
63,
1057
],
[
1057,
25,
1362
]
],
[
[
491,
24,
1580
],
[
1580,
64,
1362
]
]
] | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
]
] | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Olaparib
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may lead to a major life threatening interaction when taken with Olaparib
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Olaparib
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Olaparib
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol and Stiripentol may lead to a major life threatening interaction when taken with Olaparib |
DB01125 | DB06186 | 279 | 1,439 | [
"DDInter98",
"DDInter969"
] | Anisindione | Ipilimumab | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver. | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011. | Major | 2 | [
[
[
279,
25,
1439
]
],
[
[
279,
24,
617
],
[
617,
24,
1439
]
],
[
[
279,
63,
912
],
[
912,
24,
1439
]
],
[
[
279,
25,
1468
],
[
1468,
63,
1439
]
],
[
[
279,
64,
112
],
[
112,
24,
1439
]
],
[
[
279,
24,
1019
],
[
1019,
63,
1439
]
],
[
[
279,
25,
4
],
[
4,
24,
1439
]
],
[
[
279,
62,
467
],
[
467,
24,
1439
]
],
[
[
279,
25,
1409
],
[
1409,
64,
1439
]
],
[
[
279,
24,
1510
],
[
1510,
64,
1439
]
]
] | [
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ipilimumab"
]
],
[
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Anisindione",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ipilimumab"
]
],
[
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ipilimumab"
]
]
] | Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Anisindione may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Anisindione may lead to a major life threatening interaction when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Anisindione may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Anisindione may cause a minor interaction that can limit clinical effects when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Anisindione may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Ipilimumab
Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Ipilimumab |
DB00283 | DB01075 | 701 | 1,376 | [
"DDInter395",
"DDInter569"
] | Clemastine | Diphenhydramine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use [L5263, L5281, L5287]. Diphenhydramine is also used in combination with as the anti-nausea drug where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system . Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties. | Moderate | 1 | [
[
[
701,
24,
1376
]
],
[
[
701,
24,
649
],
[
649,
63,
1376
]
],
[
[
701,
24,
128
],
[
128,
24,
1376
]
],
[
[
701,
35,
1594
],
[
1594,
24,
1376
]
],
[
[
701,
63,
357
],
[
357,
24,
1376
]
],
[
[
701,
1,
11268
],
[
11268,
40,
1376
]
],
[
[
701,
25,
675
],
[
675,
25,
1376
]
],
[
[
701,
6,
12523
],
[
12523,
45,
1376
]
],
[
[
701,
21,
28921
],
[
28921,
60,
1376
]
],
[
[
701,
23,
771
],
[
771,
62,
1376
]
]
] | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzatropine"
],
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound)",
"Cloperastine"
],
[
"Cloperastine",
"{u} (Compound) resembles {v} (Compound)",
"Diphenhydramine"
]
],
[
[
"Clemastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Clemastine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Diphenhydramine"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Diphenhydramine"
]
],
[
[
"Clemastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diphenhydramine"
]
]
] | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Clemastine (Compound) resembles Cloperastine (Compound) and Cloperastine (Compound) resembles Diphenhydramine (Compound)
Clemastine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Diphenhydramine
Clemastine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Diphenhydramine (Compound)
Clemastine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Diphenhydramine (Compound)
Clemastine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Diphenhydramine |
DB06616 | DB11003 | 594 | 748 | [
"DDInter224",
"DDInter100"
] | Bosutinib | Anthrax vaccine | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world. | Moderate | 1 | [
[
[
594,
24,
748
]
],
[
[
594,
25,
676
],
[
676,
63,
748
]
],
[
[
594,
63,
1683
],
[
1683,
24,
748
]
],
[
[
594,
24,
1619
],
[
1619,
63,
748
]
],
[
[
594,
64,
1057
],
[
1057,
24,
748
]
],
[
[
594,
25,
1011
],
[
1011,
24,
748
]
],
[
[
594,
24,
713
],
[
713,
24,
748
]
],
[
[
594,
25,
676
],
[
676,
64,
322
],
[
322,
24,
748
]
],
[
[
594,
63,
1683
],
[
1683,
63,
322
],
[
322,
24,
748
]
],
[
[
594,
24,
1619
],
[
1619,
63,
322
],
[
322,
24,
748
]
]
] | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
]
] | Bosutinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Bosutinib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Bosutinib may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Bosutinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine |
DB06414 | DB06791 | 655 | 1,446 | [
"DDInter703",
"DDInter1021"
] | Etravirine | Lanreotide | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. Etravarine must always be used in combination with other antiretroviral drugs. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV- | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. | Moderate | 1 | [
[
[
655,
24,
1446
]
],
[
[
655,
24,
466
],
[
466,
62,
1446
]
],
[
[
655,
25,
1017
],
[
1017,
63,
1446
]
],
[
[
655,
24,
405
],
[
405,
63,
1446
]
],
[
[
655,
63,
1324
],
[
1324,
24,
1446
]
],
[
[
655,
24,
466
],
[
466,
63,
907
],
[
907,
62,
1446
]
],
[
[
655,
25,
1017
],
[
1017,
25,
466
],
[
466,
62,
1446
]
],
[
[
655,
24,
405
],
[
405,
24,
1017
],
[
1017,
63,
1446
]
],
[
[
655,
24,
159
],
[
159,
62,
466
],
[
466,
62,
1446
]
],
[
[
655,
63,
1324
],
[
1324,
24,
466
],
[
466,
62,
1446
]
]
] | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lanreotide"
]
],
[
[
"Etravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lanreotide"
]
],
[
[
"Etravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lanreotide"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lanreotide"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lanreotide"
]
]
] | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Lanreotide
Etravirine may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Lanreotide
Etravirine may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Lanreotide
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Lanreotide
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Lanreotide |
DB04837 | DB14881 | 649 | 180 | [
"DDInter407",
"DDInter1329"
] | Clofedanol | Oliceridine | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists.[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and respiratory depression.[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin.[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™. | Moderate | 1 | [
[
[
649,
24,
180
]
],
[
[
649,
63,
401
],
[
401,
24,
180
]
],
[
[
649,
24,
516
],
[
516,
24,
180
]
],
[
[
649,
1,
888
],
[
888,
24,
180
]
],
[
[
649,
74,
662
],
[
662,
24,
180
]
],
[
[
649,
40,
11
],
[
11,
25,
180
]
],
[
[
649,
63,
475
],
[
475,
25,
180
]
],
[
[
649,
63,
401
],
[
401,
62,
112
],
[
112,
23,
180
]
],
[
[
649,
63,
100
],
[
100,
24,
401
],
[
401,
24,
180
]
],
[
[
649,
24,
516
],
[
516,
63,
401
],
[
401,
24,
180
]
]
] | [
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oliceridine"
]
],
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
]
] | Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Clofedanol (Compound) resembles Tamoxifen (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Clofedanol (Compound) resembles Carbinoxamine (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Clofedanol (Compound) resembles Toremifene (Compound) and Toremifene may lead to a major life threatening interaction when taken with Oliceridine
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Oliceridine
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine |
DB00334 | DB01166 | 867 | 477 | [
"DDInter1326",
"DDInter379"
] | Olanzapine | Cilostazol | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Moderate | 1 | [
[
[
867,
24,
477
]
],
[
[
867,
6,
8374
],
[
8374,
45,
477
]
],
[
[
867,
23,
112
],
[
112,
23,
477
]
],
[
[
867,
24,
820
],
[
820,
63,
477
]
],
[
[
867,
24,
888
],
[
888,
24,
477
]
],
[
[
867,
1,
623
],
[
623,
63,
477
]
],
[
[
867,
1,
87
],
[
87,
24,
477
]
],
[
[
867,
63,
618
],
[
618,
24,
477
]
],
[
[
867,
24,
11
],
[
11,
25,
477
]
],
[
[
867,
24,
877
],
[
877,
64,
477
]
]
] | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Olanzapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cilostazol"
]
],
[
[
"Olanzapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Amoxapine"
],
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
]
]
] | Olanzapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Olanzapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Olanzapine (Compound) resembles Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Cilostazol
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Cilostazol |
DB01131 | DB11901 | 1,243 | 913 | [
"DDInter1531",
"DDInter107"
] | Proguanil | Apalutamide | Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer . | Moderate | 1 | [
[
[
1243,
24,
913
]
],
[
[
1243,
63,
279
],
[
279,
24,
913
]
],
[
[
1243,
24,
286
],
[
286,
24,
913
]
],
[
[
1243,
24,
283
],
[
283,
64,
913
]
],
[
[
1243,
24,
436
],
[
436,
25,
913
]
],
[
[
1243,
63,
279
],
[
279,
64,
112
],
[
112,
23,
913
]
],
[
[
1243,
24,
286
],
[
286,
63,
600
],
[
600,
24,
913
]
],
[
[
1243,
63,
126
],
[
126,
25,
112
],
[
112,
23,
913
]
],
[
[
1243,
24,
283
],
[
283,
64,
312
],
[
312,
23,
913
]
],
[
[
1243,
5,
11571
],
[
11571,
44,
436
],
[
436,
25,
913
]
]
] | [
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Artemether"
],
[
"Artemether",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Proguanil",
"{u} (Compound) treats {v} (Disease)",
"malaria"
],
[
"malaria",
"{u} (Disease) is treated by {v} (Compound)",
"Artemether"
],
[
"Artemether",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
]
] | Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Apalutamide
Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Artemether and Artemether may lead to a major life threatening interaction when taken with Apalutamide
Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may lead to a major life threatening interaction when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Proguanil (Compound) treats malaria (Disease) and malaria (Disease) is treated by Artemether (Compound) and Artemether may lead to a major life threatening interaction when taken with Apalutamide |
DB01254 | DB15982 | 1,213 | 1,339 | [
"DDInter484",
"DDInter193"
] | Dasatinib | Berotralstat | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat is strictly used to prevent, but not treat, these attacks. Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. Berotralstat was approved by the European Commission on April 30, 2021 and by Health Canada on June 06, 2022. | Moderate | 1 | [
[
[
1213,
24,
1339
]
],
[
[
1213,
63,
1101
],
[
1101,
23,
1339
]
],
[
[
1213,
24,
283
],
[
283,
23,
1339
]
],
[
[
1213,
24,
761
],
[
761,
24,
1339
]
],
[
[
1213,
25,
351
],
[
351,
24,
1339
]
],
[
[
1213,
63,
1486
],
[
1486,
24,
1339
]
],
[
[
1213,
64,
11
],
[
11,
24,
1339
]
],
[
[
1213,
25,
760
],
[
760,
25,
1339
]
],
[
[
1213,
24,
1619
],
[
1619,
25,
1339
]
],
[
[
1213,
64,
609
],
[
609,
25,
1339
]
]
] | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Berotralstat"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Berotralstat"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
]
]
] | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Dasatinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Dasatinib may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Dasatinib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Berotralstat
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Berotralstat
Dasatinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Berotralstat |
DB01069 | DB01080 | 401 | 855 | [
"DDInter1533",
"DDInter1933"
] | Promethazine | Vigabatrin | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. It was first introduced as an antiepileptic agent in the United Kingdom in 1989 and was used extensively until 1997, when an association with vision loss became apparent. Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual deficits.[L13661,A202124] | Moderate | 1 | [
[
[
401,
24,
855
]
],
[
[
401,
21,
28975
],
[
28975,
60,
855
]
],
[
[
401,
24,
407
],
[
407,
63,
855
]
],
[
[
401,
63,
1010
],
[
1010,
24,
855
]
],
[
[
401,
25,
1311
],
[
1311,
63,
855
]
],
[
[
401,
24,
1376
],
[
1376,
24,
855
]
],
[
[
401,
63,
888
],
[
888,
25,
855
]
],
[
[
401,
25,
1487
],
[
1487,
64,
855
]
],
[
[
401,
21,
28975
],
[
28975,
60,
537
],
[
537,
63,
855
]
],
[
[
401,
21,
28719
],
[
28719,
60,
11334
],
[
11334,
1,
855
]
]
] | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vigabatrin"
]
],
[
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Tension"
],
[
"Tension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vigabatrin"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vigabatrin"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vigabatrin"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vigabatrin"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vigabatrin"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vigabatrin"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vigabatrin"
]
],
[
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Tension"
],
[
"Tension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vigabatrin"
]
],
[
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"L-Glutamine"
],
[
"L-Glutamine",
"{u} (Compound) resembles {v} (Compound)",
"Vigabatrin"
]
]
] | Promethazine (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Vigabatrin (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Vigabatrin
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Vigabatrin
Promethazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Vigabatrin
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Vigabatrin
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Vigabatrin
Promethazine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Vigabatrin
Promethazine (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Cyclizine (Compound) and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Vigabatrin
Promethazine (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by L-Glutamine (Compound) and L-Glutamine (Compound) resembles Vigabatrin (Compound) |
DB09075 | DB11703 | 498 | 405 | [
"DDInter621",
"DDInter9"
] | Edoxaban | Acalabrutinib | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib.[L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK. Nevertheless, acalabrutinib was approved under the FDA's accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib's currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials. Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib . | Major | 2 | [
[
[
498,
25,
405
]
],
[
[
498,
63,
383
],
[
383,
24,
405
]
],
[
[
498,
64,
1313
],
[
1313,
24,
405
]
],
[
[
498,
25,
1598
],
[
1598,
63,
405
]
],
[
[
498,
24,
992
],
[
992,
24,
405
]
],
[
[
498,
24,
1017
],
[
1017,
63,
405
]
],
[
[
498,
64,
804
],
[
804,
25,
405
]
],
[
[
498,
63,
1623
],
[
1623,
25,
405
]
],
[
[
498,
24,
927
],
[
927,
64,
405
]
],
[
[
498,
25,
235
],
[
235,
25,
405
]
]
] | [
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Suvorexant"
],
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
],
[
"Ginger",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfinpyrazone"
],
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
],
[
"Isavuconazonium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
]
] | Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Edoxaban may lead to a major life threatening interaction when taken with Suvorexant and Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Edoxaban may lead to a major life threatening interaction when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Ginger and Ginger may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Edoxaban may lead to a major life threatening interaction when taken with Sulfinpyrazone and Sulfinpyrazone may lead to a major life threatening interaction when taken with Acalabrutinib
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium and Isavuconazonium may lead to a major life threatening interaction when taken with Acalabrutinib
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Acalabrutinib
Edoxaban may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Acalabrutinib |
DB11799 | DB12941 | 627 | 466 | [
"DDInter205",
"DDInter481"
] | Bictegravir | Darolutamide | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019. | Moderate | 1 | [
[
[
627,
24,
466
]
],
[
[
627,
63,
1374
],
[
1374,
23,
466
]
],
[
[
627,
24,
283
],
[
283,
23,
466
]
],
[
[
627,
63,
1040
],
[
1040,
24,
466
]
],
[
[
627,
24,
1619
],
[
1619,
24,
466
]
],
[
[
627,
24,
982
],
[
982,
63,
466
]
],
[
[
627,
63,
1220
],
[
1220,
25,
466
]
],
[
[
627,
64,
129
],
[
129,
25,
466
]
],
[
[
627,
25,
913
],
[
913,
25,
466
]
],
[
[
627,
63,
1374
],
[
1374,
63,
1622
],
[
1622,
23,
466
]
]
] | [
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
]
],
[
[
"Bictegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
]
],
[
[
"Bictegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
]
],
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
]
] | Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Darolutamide
Bictegravir may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Darolutamide
Bictegravir may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Darolutamide
Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide |
DB06754 | DB11703 | 707 | 405 | [
"DDInter471",
"DDInter9"
] | Danaparoid | Acalabrutinib | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans. The active constituents are heparan, dermatan and, and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients. Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT). While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib.[L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK. Nevertheless, acalabrutinib was approved under the FDA's accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib's currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials. Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib . | Major | 2 | [
[
[
707,
25,
405
]
],
[
[
707,
63,
383
],
[
383,
24,
405
]
],
[
[
707,
24,
1427
],
[
1427,
24,
405
]
],
[
[
707,
24,
738
],
[
738,
63,
405
]
],
[
[
707,
64,
126
],
[
126,
25,
405
]
],
[
[
707,
25,
235
],
[
235,
25,
405
]
],
[
[
707,
25,
283
],
[
283,
64,
405
]
],
[
[
707,
64,
1274
],
[
1274,
37,
405
]
],
[
[
707,
63,
383
],
[
383,
24,
765
],
[
765,
24,
405
]
],
[
[
707,
63,
643
],
[
643,
63,
478
],
[
478,
24,
405
]
]
] | [
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
],
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
],
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
]
] | Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Danaparoid may lead to a major life threatening interaction when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Acalabrutinib
Danaparoid may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Acalabrutinib
Danaparoid may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Acalabrutinib
Danaparoid may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Flurbiprofen may lead to a major life threatening interaction when taken with Acalabrutinib
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib |
DB01067 | DB08899 | 959 | 129 | [
"DDInter826",
"DDInter649"
] | Glipizide | Enzalutamide | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Moderate | 1 | [
[
[
959,
24,
129
]
],
[
[
959,
6,
8374
],
[
8374,
45,
129
]
],
[
[
959,
21,
28703
],
[
28703,
60,
129
]
],
[
[
959,
63,
1247
],
[
1247,
23,
129
]
],
[
[
959,
24,
1060
],
[
1060,
62,
129
]
],
[
[
959,
63,
529
],
[
529,
24,
129
]
],
[
[
959,
24,
1206
],
[
1206,
24,
129
]
],
[
[
959,
24,
1040
],
[
1040,
63,
129
]
],
[
[
959,
25,
1539
],
[
1539,
24,
129
]
],
[
[
959,
64,
956
],
[
956,
24,
129
]
]
] | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Glipizide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Glipizide",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
],
[
"Gemfibrozil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Glipizide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Glipizide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
]
] | Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Glipizide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil and Gemfibrozil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Glipizide may lead to a major life threatening interaction when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Glipizide may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide |
DB00563 | DB01294 | 663 | 266 | [
"DDInter1174",
"DDInter215"
] | Methotrexate | Bismuth subsalicylate | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth subsalicylate has been around for over 100 years: it was originally developed in 1901 for hygienic use and sanitation for cholera infection.[A230728, A230773] Bismuth subsalicylate was first approved by the FDA in 1939 and is now mainly used to relieve nausea, diarrhea, and gastrointestinal discomfort. It is an active ingredient found in Pepto-Bismol, a common over-the-counter medication that is used to temporarily treat discomforts of the stomach and gastrointestinal tract. Bismuth subsalicylate is a component of HELIDAC Therapy (bismuth subsalicylate, [metronidazole], and [tetracycline]), which is a treatment regimen indicated for the eradication of _H. pylori_ for treatment of patients with _H. pylori_ infection and duodenal ulcer disease. | Major | 2 | [
[
[
663,
25,
266
]
],
[
[
663,
6,
1829
],
[
1829,
45,
266
]
],
[
[
663,
7,
7720
],
[
7720,
45,
266
]
],
[
[
663,
21,
28643
],
[
28643,
60,
266
]
],
[
[
663,
24,
1620
],
[
1620,
24,
266
]
],
[
[
663,
23,
126
],
[
126,
24,
266
]
],
[
[
663,
63,
964
],
[
964,
24,
266
]
],
[
[
663,
6,
1829
],
[
1829,
31,
2675
],
[
2675,
45,
266
]
],
[
[
663,
7,
7720
],
[
7720,
46,
1061
],
[
1061,
24,
266
]
],
[
[
663,
21,
28643
],
[
28643,
60,
1347
],
[
1347,
24,
266
]
]
] | [
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Bismuth subsalicylate"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",
"Bismuth subsalicylate"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bismuth subsalicylate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) interacts with {v} (Gene) and {u} (Gene) regulates {v} (Gene)",
"TF"
],
[
"TF",
"{u} (Gene) is bound by {v} (Compound)",
"Bismuth subsalicylate"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
]
] | Methotrexate (Compound) binds ALB (Gene) and ALB (Gene) is bound by Bismuth subsalicylate (Compound)
Methotrexate (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Bismuth subsalicylate (Compound)
Methotrexate (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Bismuth subsalicylate (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate
Methotrexate (Compound) binds ALB (Gene) and ALB (Gene) interacts with TF (Gene) and ALB (Gene) regulates TF (Gene) and TF (Gene) is bound by Bismuth subsalicylate (Compound)
Methotrexate (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate
Methotrexate (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Clopidogrel (Compound) and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate |
DB00208 | DB06603 | 1,018 | 39 | [
"DDInter1804",
"DDInter1387"
] | Ticlopidine | Panobinostat | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Major | 2 | [
[
[
1018,
25,
39
]
],
[
[
1018,
23,
479
],
[
479,
23,
39
]
],
[
[
1018,
23,
1627
],
[
1627,
63,
39
]
],
[
[
1018,
24,
506
],
[
506,
24,
39
]
],
[
[
1018,
24,
578
],
[
578,
63,
39
]
],
[
[
1018,
63,
1560
],
[
1560,
24,
39
]
],
[
[
1018,
25,
4
],
[
4,
24,
39
]
],
[
[
1018,
23,
1220
],
[
1220,
24,
39
]
],
[
[
1018,
25,
503
],
[
503,
64,
39
]
],
[
[
1018,
24,
1237
],
[
1237,
25,
39
]
]
] | [
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Panobinostat"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
],
[
"Zanubrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
]
] | Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Ticlopidine may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Ticlopidine may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Panobinostat
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may lead to a major life threatening interaction when taken with Panobinostat |
DB00254 | DB01592 | 964 | 1,596 | [
"DDInter598",
"DDInter975"
] | Doxycycline | Iron | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria. | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. | Moderate | 1 | [
[
[
964,
24,
1596
]
],
[
[
964,
24,
1096
],
[
1096,
23,
1596
]
],
[
[
964,
24,
1384
],
[
1384,
63,
1596
]
],
[
[
964,
1,
1669
],
[
1669,
24,
1596
]
],
[
[
964,
24,
1117
],
[
1117,
24,
1596
]
],
[
[
964,
40,
1620
],
[
1620,
24,
1596
]
],
[
[
964,
24,
1096
],
[
1096,
21,
29243
],
[
29243,
60,
1596
]
],
[
[
964,
24,
1384
],
[
1384,
62,
752
],
[
752,
23,
1596
]
],
[
[
964,
1,
1669
],
[
1669,
24,
1193
],
[
1193,
62,
1596
]
],
[
[
964,
24,
1475
],
[
1475,
63,
1096
],
[
1096,
23,
1596
]
]
] | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
],
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
],
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Wheezing"
],
[
"Wheezing",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iron"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
],
[
"Magaldrate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
],
[
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
],
[
"Sodium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
]
] | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Iron
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Iron
Doxycycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Iron
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate and Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Iron
Doxycycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Iron
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) causes Wheezing (Side Effect) and Wheezing (Side Effect) is caused by Iron (Compound)
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Iron
Doxycycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Iron
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate and Sodium citrate may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Iron |
DB00454 | DB00835 | 1,349 | 100 | [
"DDInter1150",
"DDInter245"
] | Meperidine | Brompheniramine | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
1349,
24,
100
]
],
[
[
1349,
24,
832
],
[
832,
24,
100
]
],
[
[
1349,
63,
128
],
[
128,
24,
100
]
],
[
[
1349,
24,
649
],
[
649,
63,
100
]
],
[
[
1349,
6,
8374
],
[
8374,
45,
100
]
],
[
[
1349,
25,
1053
],
[
1053,
63,
100
]
],
[
[
1349,
40,
411
],
[
411,
63,
100
]
],
[
[
1349,
64,
475
],
[
475,
24,
100
]
],
[
[
1349,
24,
662
],
[
662,
35,
100
]
],
[
[
1349,
24,
1376
],
[
1376,
74,
100
]
]
] | [
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Meperidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Brompheniramine"
]
],
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Meperidine",
"{u} (Compound) resembles {v} (Compound)",
"Remifentanil"
],
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
]
] | Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Meperidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Brompheniramine (Compound)
Meperidine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Meperidine (Compound) resembles Remifentanil (Compound) and Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Meperidine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Brompheniramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Brompheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine |
DB08901 | DB14444 | 1,468 | 151 | [
"DDInter1492",
"DDInter924"
] | Ponatinib | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to. There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability. | Moderate | 1 | [
[
[
1468,
24,
151
]
],
[
[
1468,
63,
66
],
[
66,
24,
151
]
],
[
[
1468,
24,
1619
],
[
1619,
24,
151
]
],
[
[
1468,
64,
397
],
[
397,
24,
151
]
],
[
[
1468,
25,
375
],
[
375,
24,
151
]
],
[
[
1468,
74,
1419
],
[
1419,
24,
151
]
],
[
[
1468,
25,
676
],
[
676,
63,
151
]
],
[
[
1468,
63,
66
],
[
66,
24,
134
],
[
134,
24,
151
]
],
[
[
1468,
63,
134
],
[
134,
63,
66
],
[
66,
24,
151
]
],
[
[
1468,
24,
1619
],
[
1619,
63,
66
],
[
66,
24,
151
]
]
] | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Plicamycin"
],
[
"Plicamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Ponatinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
]
] | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ponatinib may lead to a major life threatening interaction when taken with Plicamycin and Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ponatinib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ponatinib (Compound) resembles Imatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ponatinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) |
DB01075 | DB13913 | 1,376 | 1,536 | [
"DDInter569",
"DDInter175"
] | Diphenhydramine | Belladonna | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed | Belladonna, also known as atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family _Solanaceae_. Its roots, leaves and fruits contain , , and mostly, . These alkaloids are naturally-occurring muscarinic antagonists. is a non-selective muscarinic antagonist that is mainly used as an adjunct for anaesthesia. The name "belladonna" originates from the Italian words "beautiful woman" and the historical use of herb eye-drops by women to dilate the pupils of the eyes for aesthetic purposes. Belladonna is a poisonous plant and belladonna intoxication from accidental ingestion may result in a severe anticholinergic syndrome, which is associated with both central and peripheral manifestations . | Moderate | 1 | [
[
[
1376,
24,
1536
]
],
[
[
1376,
24,
849
],
[
849,
24,
1536
]
],
[
[
1376,
63,
128
],
[
128,
24,
1536
]
],
[
[
1376,
35,
1264
],
[
1264,
24,
1536
]
],
[
[
1376,
74,
100
],
[
100,
24,
1536
]
],
[
[
1376,
64,
1621
],
[
1621,
25,
1536
]
],
[
[
1376,
24,
849
],
[
849,
63,
128
],
[
128,
24,
1536
]
],
[
[
1376,
63,
128
],
[
128,
24,
849
],
[
849,
24,
1536
]
],
[
[
1376,
35,
1264
],
[
1264,
24,
849
],
[
849,
24,
1536
]
],
[
[
1376,
74,
100
],
[
100,
35,
849
],
[
849,
24,
1536
]
]
] | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Diphenhydramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Belladonna"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
]
] | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Diphenhydramine (Compound) resembles Doxepin (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Diphenhydramine (Compound) resembles Brompheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Diphenhydramine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Belladonna
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Diphenhydramine (Compound) resembles Doxepin (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Diphenhydramine (Compound) resembles Brompheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine (Compound) resembles Mepyramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna |
DB00773 | DB01177 | 896 | 77 | [
"DDInter702",
"DDInter904"
] | Etoposide | Idarubicin | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
896,
24,
77
]
],
[
[
896,
5,
11555
],
[
11555,
44,
77
]
],
[
[
896,
6,
10417
],
[
10417,
45,
77
]
],
[
[
896,
7,
4260
],
[
4260,
46,
77
]
],
[
[
896,
54,
19254
],
[
19254,
15,
77
]
],
[
[
896,
18,
8527
],
[
8527,
57,
77
]
],
[
[
896,
7,
2900
],
[
2900,
57,
77
]
],
[
[
896,
21,
29170
],
[
29170,
60,
77
]
],
[
[
896,
23,
646
],
[
646,
23,
77
]
],
[
[
896,
62,
1467
],
[
1467,
23,
77
]
]
] | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Etoposide",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Etoposide",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Etoposide",
"{u} (Compound) upregulates {v} (Gene)",
"PLXNB2"
],
[
"PLXNB2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Etoposide",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Topoisomerase Inhibitors"
],
[
"Topoisomerase Inhibitors",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Idarubicin"
]
],
[
[
"Etoposide",
"{u} (Compound) downregulates {v} (Gene)",
"UBE2S"
],
[
"UBE2S",
"{u} (Gene) is downregulated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Etoposide",
"{u} (Compound) upregulates {v} (Gene)",
"NFKBIA"
],
[
"NFKBIA",
"{u} (Gene) is downregulated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Etoposide",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac failure congestive"
],
[
"Cardiac failure congestive",
"{u} (Side Effect) is caused by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Etoposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cinoxacin"
],
[
"Cinoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
],
[
[
"Etoposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
]
] | Etoposide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Idarubicin (Compound)
Etoposide (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Idarubicin (Compound)
Etoposide (Compound) upregulates PLXNB2 (Gene) and PLXNB2 (Gene) is upregulated by Idarubicin (Compound)
Etoposide (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class) and Topoisomerase Inhibitors (Pharmacologic Class) includes Idarubicin (Compound)
Etoposide (Compound) downregulates UBE2S (Gene) and UBE2S (Gene) is downregulated by Idarubicin (Compound)
Etoposide (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Idarubicin (Compound)
Etoposide (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) is caused by Idarubicin (Compound)
Etoposide may cause a minor interaction that can limit clinical effects when taken with Cinoxacin and Cinoxacin may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Etoposide may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Idarubicin |
DB00687 | DB10675 | 870 | 961 | [
"DDInter747",
"DDInter1065"
] | Fludrocortisone | Licorice | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Licorice allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
870,
24,
961
]
],
[
[
870,
1,
891
],
[
891,
24,
961
]
],
[
[
870,
24,
1231
],
[
1231,
24,
961
]
],
[
[
870,
63,
1214
],
[
1214,
24,
961
]
],
[
[
870,
1,
891
],
[
891,
40,
1573
],
[
1573,
24,
961
]
],
[
[
870,
1,
1573
],
[
1573,
1,
891
],
[
891,
24,
961
]
],
[
[
870,
24,
1231
],
[
1231,
63,
708
],
[
708,
24,
961
]
],
[
[
870,
63,
1214
],
[
1214,
24,
885
],
[
885,
24,
961
]
],
[
[
870,
21,
28936
],
[
28936,
60,
885
],
[
885,
24,
961
]
],
[
[
870,
1,
891
],
[
891,
24,
1231
],
[
1231,
24,
961
]
]
] | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
]
] | Fludrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Fludrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Fludrocortisone (Compound) resembles Prednisone (Compound) and Prednisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Fludrocortisone (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Epoprostenol (Compound) and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Fludrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Licorice |
DB01097 | DB11581 | 1,377 | 1,456 | [
"DDInter1033",
"DDInter1926"
] | Leflunomide | Venetoclax | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy [FDA label]. Previously, this drug was indicated only for patients with 17p gene deletion . | Major | 2 | [
[
[
1377,
25,
1456
]
],
[
[
1377,
25,
259
],
[
259,
24,
1456
]
],
[
[
1377,
24,
1129
],
[
1129,
63,
1456
]
],
[
[
1377,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
1377,
24,
248
],
[
248,
24,
1456
]
],
[
[
1377,
64,
522
],
[
522,
24,
1456
]
],
[
[
1377,
63,
126
],
[
126,
24,
1456
]
],
[
[
1377,
25,
1011
],
[
1011,
25,
1456
]
],
[
[
1377,
64,
581
],
[
581,
25,
1456
]
],
[
[
1377,
25,
1259
],
[
1259,
64,
1456
]
]
] | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
],
[
"Human adenovirus e serotype 4 strain cl-68578 antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
]
] | Leflunomide may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Leflunomide may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Leflunomide may lead to a major life threatening interaction when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Leflunomide may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Venetoclax
Leflunomide may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Venetoclax
Leflunomide may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Venetoclax |
DB00414 | DB11943 | 590 | 255 | [
"DDInter16",
"DDInter495"
] | Acetohexamide | Delafloxacin | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections. | Major | 2 | [
[
[
590,
25,
255
]
],
[
[
590,
24,
450
],
[
450,
23,
255
]
],
[
[
590,
24,
1283
],
[
1283,
24,
255
]
],
[
[
590,
63,
1645
],
[
1645,
24,
255
]
],
[
[
590,
24,
1385
],
[
1385,
63,
255
]
],
[
[
590,
24,
251
],
[
251,
25,
255
]
],
[
[
590,
63,
1179
],
[
1179,
25,
255
]
],
[
[
590,
24,
450
],
[
450,
1,
1001
],
[
1001,
23,
255
]
],
[
[
590,
24,
1532
],
[
1532,
63,
1001
],
[
1001,
23,
255
]
],
[
[
590,
24,
1283
],
[
1283,
62,
60
],
[
60,
23,
255
]
]
] | [
[
[
"Acetohexamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} (Compound) resembles {v} (Compound)",
"Mechlorethamine"
],
[
"Mechlorethamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
],
[
"Mechlorethamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
]
] | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may lead to a major life threatening interaction when taken with Delafloxacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may lead to a major life threatening interaction when taken with Delafloxacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Mechlorethamine (Compound) and Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin |
DB00745 | DB04868 | 307 | 478 | [
"DDInter1236",
"DDInter1293"
] | Modafinil | Nilotinib | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Minor | 0 | [
[
[
307,
23,
478
]
],
[
[
307,
23,
1468
],
[
1468,
63,
478
]
],
[
[
307,
6,
6017
],
[
6017,
45,
478
]
],
[
[
307,
18,
10375
],
[
10375,
57,
478
]
],
[
[
307,
21,
28963
],
[
28963,
60,
478
]
],
[
[
307,
23,
1135
],
[
1135,
62,
478
]
],
[
[
307,
24,
466
],
[
466,
62,
478
]
],
[
[
307,
24,
1040
],
[
1040,
63,
478
]
],
[
[
307,
62,
10
],
[
10,
24,
478
]
],
[
[
307,
23,
300
],
[
300,
24,
478
]
]
] | [
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Modafinil",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Modafinil",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Modafinil",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Letrozole"
],
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
]
] | Modafinil may cause a minor interaction that can limit clinical effects when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Modafinil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Modafinil (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Nilotinib (Compound)
Modafinil (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Modafinil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Modafinil may cause a minor interaction that can limit clinical effects when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Modafinil may cause a minor interaction that can limit clinical effects when taken with Letrozole and Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib |
DB00295 | DB00792 | 475 | 832 | [
"DDInter1244",
"DDInter1878"
] | Morphine | Tripelennamine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
475,
24,
832
]
],
[
[
475,
24,
100
],
[
100,
63,
832
]
],
[
[
475,
24,
649
],
[
649,
1,
832
]
],
[
[
475,
25,
508
],
[
508,
1,
832
]
],
[
[
475,
24,
1594
],
[
1594,
24,
832
]
],
[
[
475,
25,
675
],
[
675,
25,
832
]
],
[
[
475,
6,
12523
],
[
12523,
45,
832
]
],
[
[
475,
25,
252
],
[
252,
24,
832
]
],
[
[
475,
25,
759
],
[
759,
63,
832
]
],
[
[
475,
63,
352
],
[
352,
24,
832
]
]
] | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Tripelennamine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Tripelennamine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tripelennamine"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Tripelennamine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
]
] | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Tripelennamine (Compound)
Morphine may lead to a major life threatening interaction when taken with Promazine and Promazine (Compound) resembles Tripelennamine (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Morphine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Tripelennamine
Morphine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tripelennamine (Compound)
Morphine may lead to a major life threatening interaction when taken with Hydroxyzine and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Morphine may lead to a major life threatening interaction when taken with Primidone and Primidone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine |
DB00910 | DB15093 | 1,041 | 1,654 | [
"DDInter1394",
"DDInter1698"
] | Paricalcitol | Somapacitan | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020. | Moderate | 1 | [
[
[
1041,
24,
1654
]
],
[
[
1041,
24,
351
],
[
351,
24,
1654
]
],
[
[
1041,
25,
1196
],
[
1196,
24,
1654
]
],
[
[
1041,
24,
351
],
[
351,
63,
10
],
[
10,
24,
1654
]
],
[
[
1041,
24,
159
],
[
159,
63,
608
],
[
608,
23,
1654
]
],
[
[
1041,
24,
1017
],
[
1017,
62,
608
],
[
608,
23,
1654
]
],
[
[
1041,
25,
1196
],
[
1196,
24,
214
],
[
214,
24,
1654
]
],
[
[
1041,
6,
8374
],
[
8374,
45,
608
],
[
608,
23,
1654
]
],
[
[
1041,
24,
351
],
[
351,
64,
1135
],
[
1135,
24,
1654
]
],
[
[
1041,
24,
159
],
[
159,
62,
1135
],
[
1135,
24,
1654
]
]
] | [
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Paricalcitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somapacitan"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somapacitan"
]
],
[
[
"Paricalcitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Paricalcitol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somapacitan"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
]
] | Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Paricalcitol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Paricalcitol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Paricalcitol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan |
DB00281 | DB04855 | 608 | 540 | [
"DDInter1066",
"DDInter602"
] | Lidocaine | Dronedarone | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally, the methyl sulfonyl group in its structure renders dronedarone to be more lipophilic with a shorter half-life than amiodarone. This ultimately leads to reduced tissue accumulation of the drug and decreased risk for organ toxicities, such as thyroid and pulmonary toxicities. Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone. | Moderate | 1 | [
[
[
608,
24,
540
]
],
[
[
608,
24,
347
],
[
347,
40,
540
]
],
[
[
608,
64,
228
],
[
228,
40,
540
]
],
[
[
608,
6,
8374
],
[
8374,
45,
540
]
],
[
[
608,
21,
28666
],
[
28666,
60,
540
]
],
[
[
608,
23,
1220
],
[
1220,
24,
540
]
],
[
[
608,
24,
214
],
[
214,
63,
540
]
],
[
[
608,
24,
629
],
[
629,
24,
540
]
],
[
[
608,
23,
1040
],
[
1040,
63,
540
]
],
[
[
608,
62,
1324
],
[
1324,
24,
540
]
]
] | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibutilide"
],
[
"Ibutilide",
"{u} (Compound) resembles {v} (Compound)",
"Dronedarone"
]
],
[
[
"Lidocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dofetilide"
],
[
"Dofetilide",
"{u} (Compound) resembles {v} (Compound)",
"Dronedarone"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dronedarone"
]
],
[
[
"Lidocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dronedarone"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
]
] | Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Ibutilide and Ibutilide (Compound) resembles Dronedarone (Compound)
Lidocaine may lead to a major life threatening interaction when taken with Dofetilide and Dofetilide (Compound) resembles Dronedarone (Compound)
Lidocaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dronedarone (Compound)
Lidocaine (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Dronedarone (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone |
DB01155 | DB09330 | 872 | 985 | [
"DDInter813",
"DDInter1352"
] | Gemifloxacin | Osimertinib | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931] | Major | 2 | [
[
[
872,
25,
985
]
],
[
[
872,
62,
112
],
[
112,
23,
985
]
],
[
[
872,
62,
134
],
[
134,
24,
985
]
],
[
[
872,
63,
480
],
[
480,
24,
985
]
],
[
[
872,
24,
657
],
[
657,
63,
985
]
],
[
[
872,
24,
28
],
[
28,
24,
985
]
],
[
[
872,
25,
1220
],
[
1220,
24,
985
]
],
[
[
872,
64,
126
],
[
126,
24,
985
]
],
[
[
872,
64,
11
],
[
11,
25,
985
]
],
[
[
872,
24,
594
],
[
594,
25,
985
]
]
] | [
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
]
] | Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Gemifloxacin may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Gemifloxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Gemifloxacin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Osimertinib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Osimertinib |
DB00201 | DB01065 | 1,684 | 43 | [
"DDInter263",
"DDInter1142"
] | Caffeine | Melatonin | Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine].[A187691,L9851] It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, which are different than coffee beans. Caffeine is also used in a variety of cosmetic products and can be administered topically, orally, by inhalation, or by injection. The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999. According to an article from 2017, more than 15 million babies are born prematurely worldwide. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | Minor | 0 | [
[
[
1684,
23,
43
]
],
[
[
1684,
6,
6017
],
[
6017,
45,
43
]
],
[
[
1684,
21,
29231
],
[
29231,
60,
43
]
],
[
[
1684,
23,
752
],
[
752,
23,
43
]
],
[
[
1684,
24,
1297
],
[
1297,
62,
43
]
],
[
[
1684,
24,
985
],
[
985,
63,
43
]
],
[
[
1684,
24,
702
],
[
702,
24,
43
]
],
[
[
1684,
6,
6017
],
[
6017,
45,
11490
],
[
11490,
40,
43
]
],
[
[
1684,
6,
7950
],
[
7950,
45,
598
],
[
598,
1,
43
]
],
[
[
1684,
6,
9842
],
[
9842,
45,
126
],
[
126,
24,
43
]
]
] | [
[
[
"Caffeine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Melatonin"
]
],
[
[
"Caffeine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Melatonin"
]
],
[
[
"Caffeine",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Melatonin"
]
],
[
[
"Caffeine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Melatonin"
]
],
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Melatonin"
]
],
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melatonin"
]
],
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melatonin"
]
],
[
[
"Caffeine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Agomelatine"
],
[
"Agomelatine",
"{u} (Compound) resembles {v} (Compound)",
"Melatonin"
]
],
[
[
"Caffeine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Nabumetone"
],
[
"Nabumetone",
"{u} (Compound) resembles {v} (Compound)",
"Melatonin"
]
],
[
[
"Caffeine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A1"
],
[
"CYP1A1",
"{u} (Gene) is bound by {v} (Compound)",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melatonin"
]
]
] | Caffeine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Melatonin (Compound)
Caffeine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Melatonin (Compound)
Caffeine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Melatonin
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Melatonin
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Melatonin
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Melatonin
Caffeine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Agomelatine (Compound) and Agomelatine (Compound) resembles Melatonin (Compound)
Caffeine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Nabumetone (Compound) and Nabumetone (Compound) resembles Melatonin (Compound)
Caffeine (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Melatonin |
DB00372 | DB00880 | 999 | 359 | [
"DDInter1793",
"DDInter360"
] | Thiethylperazine | Chlorothiazide | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Moderate | 1 | [
[
[
999,
24,
359
]
],
[
[
999,
24,
1577
],
[
1577,
1,
359
]
],
[
[
999,
24,
1123
],
[
1123,
23,
359
]
],
[
[
999,
63,
352
],
[
352,
23,
359
]
],
[
[
999,
24,
1511
],
[
1511,
62,
359
]
],
[
[
999,
24,
1130
],
[
1130,
63,
359
]
],
[
[
999,
63,
176
],
[
176,
24,
359
]
],
[
[
999,
24,
530
],
[
530,
24,
359
]
],
[
[
999,
25,
593
],
[
593,
63,
359
]
],
[
[
999,
23,
286
],
[
286,
63,
359
]
]
] | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
],
[
"Propantheline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
]
] | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a minor interaction that can limit clinical effects when taken with Chlorothiazide
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a minor interaction that can limit clinical effects when taken with Chlorothiazide
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a minor interaction that can limit clinical effects when taken with Chlorothiazide
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide
Thiethylperazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide |
DB00916 | DB00934 | 112 | 413 | [
"DDInter1202",
"DDInter1124"
] | Metronidazole | Maprotiline | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections. | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression. | Minor | 0 | [
[
[
112,
23,
413
]
],
[
[
112,
62,
1302
],
[
1302,
40,
413
]
],
[
[
112,
62,
847
],
[
847,
1,
413
]
],
[
[
112,
21,
28880
],
[
28880,
60,
413
]
],
[
[
112,
23,
1151
],
[
1151,
63,
413
]
],
[
[
112,
62,
1424
],
[
1424,
24,
413
]
],
[
[
112,
63,
543
],
[
543,
24,
413
]
],
[
[
112,
24,
1662
],
[
1662,
63,
413
]
],
[
[
112,
23,
1559
],
[
1559,
24,
413
]
],
[
[
112,
23,
478
],
[
478,
64,
413
]
]
] | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Maprotiline"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Protriptyline"
],
[
"Protriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Maprotiline"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Maprotiline"
]
],
[
[
"Metronidazole",
"{u} (Compound) causes {v} (Side Effect)",
"Angiopathy"
],
[
"Angiopathy",
"{u} (Side Effect) is caused by {v} (Compound)",
"Maprotiline"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Maprotiline"
]
]
] | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Protriptyline and Protriptyline (Compound) resembles Maprotiline (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Atomoxetine and Atomoxetine (Compound) resembles Maprotiline (Compound)
Metronidazole (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Maprotiline (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Maprotiline
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Maprotiline
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Maprotiline
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Maprotiline
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Maprotiline
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Maprotiline |
DB00794 | DB12364 | 759 | 1,421 | [
"DDInter1521",
"DDInter200"
] | Primidone | Betrixaban | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients . | Moderate | 1 | [
[
[
759,
24,
1421
]
],
[
[
759,
25,
1513
],
[
1513,
24,
1421
]
],
[
[
759,
24,
971
],
[
971,
24,
1421
]
],
[
[
759,
40,
362
],
[
362,
24,
1421
]
],
[
[
759,
1,
697
],
[
697,
24,
1421
]
],
[
[
759,
63,
888
],
[
888,
24,
1421
]
],
[
[
759,
24,
392
],
[
392,
25,
1421
]
],
[
[
759,
25,
741
],
[
741,
25,
1421
]
],
[
[
759,
63,
1424
],
[
1424,
25,
1421
]
],
[
[
759,
64,
126
],
[
126,
25,
1421
]
]
] | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apremilast"
],
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
],
[
"Rolapitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
]
] | Primidone may lead to a major life threatening interaction when taken with Apremilast and Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Primidone (Compound) resembles Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Primidone (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Betrixaban
Primidone may lead to a major life threatening interaction when taken with Rolapitant and Rolapitant may lead to a major life threatening interaction when taken with Betrixaban
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Betrixaban
Primidone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Betrixaban |
DB00323 | DB08870 | 1,062 | 850 | [
"DDInter1829",
"DDInter228"
] | Tolcapone | Brentuximab vedotin | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease. | Moderate | 1 | [
[
[
1062,
24,
850
]
],
[
[
1062,
24,
267
],
[
267,
24,
850
]
],
[
[
1062,
63,
305
],
[
305,
24,
850
]
],
[
[
1062,
24,
384
],
[
384,
63,
850
]
],
[
[
1062,
40,
24
],
[
24,
24,
850
]
],
[
[
1062,
25,
1510
],
[
1510,
64,
850
]
],
[
[
1062,
25,
1377
],
[
1377,
25,
850
]
],
[
[
1062,
24,
267
],
[
267,
24,
788
],
[
788,
24,
850
]
],
[
[
1062,
63,
305
],
[
305,
24,
788
],
[
788,
24,
850
]
],
[
[
1062,
24,
384
],
[
384,
63,
788
],
[
788,
24,
850
]
]
] | [
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tolcapone",
"{u} (Compound) resembles {v} (Compound)",
"Tolmetin"
],
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tolcapone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tolcapone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
]
] | Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tolcapone (Compound) resembles Tolmetin (Compound) and Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tolcapone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin
Tolcapone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin |
DB00795 | DB00812 | 50 | 998 | [
"DDInter1725",
"DDInter1451"
] | Sulfasalazine | Phenylbutazone | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulf | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822) | Moderate | 1 | [
[
[
50,
24,
998
]
],
[
[
50,
63,
362
],
[
362,
1,
998
]
],
[
[
50,
24,
97
],
[
97,
40,
998
]
],
[
[
50,
34,
7720
],
[
7720,
45,
998
]
],
[
[
50,
6,
10522
],
[
10522,
45,
998
]
],
[
[
50,
7,
7273
],
[
7273,
46,
998
]
],
[
[
50,
24,
484
],
[
484,
63,
998
]
],
[
[
50,
24,
1132
],
[
1132,
24,
998
]
],
[
[
50,
63,
912
],
[
912,
24,
998
]
],
[
[
50,
40,
712
],
[
712,
63,
998
]
]
] | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Phenylbutazone"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
],
[
"Oxaprozin",
"{u} (Compound) resembles {v} (Compound)",
"Phenylbutazone"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",
"Phenylbutazone"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) binds {v} (Gene)",
"PTGS1"
],
[
"PTGS1",
"{u} (Gene) is bound by {v} (Compound)",
"Phenylbutazone"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) upregulates {v} (Gene)",
"GPATCH8"
],
[
"GPATCH8",
"{u} (Gene) is upregulated by {v} (Compound)",
"Phenylbutazone"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gentamicin"
],
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) resembles {v} (Compound)",
"Olsalazine"
],
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
]
] | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenylbutazone (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin (Compound) resembles Phenylbutazone (Compound)
Sulfasalazine (Compound) binds PTGS2 (Gene) and Sulfasalazine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Phenylbutazone (Compound)
Sulfasalazine (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Phenylbutazone (Compound)
Sulfasalazine (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Phenylbutazone (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone
Sulfasalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone |
DB05676 | DB08912 | 1,513 | 1,040 | [
"DDInter111",
"DDInter462"
] | Apremilast | Dabrafenib | Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. | Moderate | 1 | [
[
[
1513,
24,
1040
]
],
[
[
1513,
63,
1101
],
[
1101,
23,
1040
]
],
[
[
1513,
25,
129
],
[
129,
24,
1040
]
],
[
[
1513,
24,
868
],
[
868,
24,
1040
]
],
[
[
1513,
64,
651
],
[
651,
24,
1040
]
],
[
[
1513,
63,
152
],
[
152,
24,
1040
]
],
[
[
1513,
24,
1678
],
[
1678,
63,
1040
]
],
[
[
1513,
25,
913
],
[
913,
63,
1040
]
],
[
[
1513,
62,
307
],
[
307,
24,
1040
]
],
[
[
1513,
24,
124
],
[
124,
64,
1040
]
]
] | [
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dabrafenib"
]
],
[
[
"Apremilast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Apremilast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosentan"
],
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
],
[
"Lesinurad",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Apremilast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Apremilast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
]
]
] | Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Apremilast may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Apremilast may lead to a major life threatening interaction when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Bosentan and Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad and Lesinurad may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Apremilast may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Apremilast may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Dabrafenib |
DB00041 | DB01142 | 1,648 | 1,264 | [
"DDInter38",
"DDInter593"
] | Aldesleukin | Doxepin | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics. | Moderate | 1 | [
[
[
1648,
24,
1264
]
],
[
[
1648,
24,
508
],
[
508,
24,
1264
]
],
[
[
1648,
24,
1405
],
[
1405,
25,
1264
]
],
[
[
1648,
24,
471
],
[
471,
23,
1264
]
],
[
[
1648,
24,
957
],
[
957,
63,
1264
]
],
[
[
1648,
25,
770
],
[
770,
24,
1264
]
],
[
[
1648,
23,
1539
],
[
1539,
63,
1264
]
],
[
[
1648,
23,
739
],
[
739,
24,
1264
]
],
[
[
1648,
23,
246
],
[
246,
25,
1264
]
],
[
[
1648,
25,
497
],
[
497,
64,
1264
]
]
] | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
],
[
"Acetazolamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxepin"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
],
[
"Paraldehyde",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
]
] | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may lead to a major life threatening interaction when taken with Doxepin
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide and Acetazolamide may cause a minor interaction that can limit clinical effects when taken with Doxepin
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde and Paraldehyde may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Aldesleukin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Doxepin
Aldesleukin may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Doxepin |
DB00443 | DB09118 | 251 | 1,580 | [
"DDInter195",
"DDInter1711"
] | Betamethasone | Stiripentol | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit. | Moderate | 1 | [
[
[
251,
24,
1580
]
],
[
[
251,
24,
283
],
[
283,
63,
1580
]
],
[
[
251,
24,
473
],
[
473,
24,
1580
]
],
[
[
251,
62,
1018
],
[
1018,
24,
1580
]
],
[
[
251,
1,
1573
],
[
1573,
24,
1580
]
],
[
[
251,
63,
1324
],
[
1324,
24,
1580
]
],
[
[
251,
25,
976
],
[
976,
24,
1580
]
],
[
[
251,
25,
676
],
[
676,
63,
1580
]
],
[
[
251,
40,
167
],
[
167,
24,
1580
]
],
[
[
251,
24,
1604
],
[
1604,
64,
1580
]
]
] | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
]
] | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Betamethasone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Betamethasone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Betamethasone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Stiripentol |
DB01097 | DB09078 | 1,377 | 1,228 | [
"DDInter1033",
"DDInter1036"
] | Leflunomide | Lenvatinib | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib. | Major | 2 | [
[
[
1377,
25,
1228
]
],
[
[
1377,
63,
112
],
[
112,
23,
1228
]
],
[
[
1377,
64,
463
],
[
463,
23,
1228
]
],
[
[
1377,
25,
609
],
[
609,
24,
1228
]
],
[
[
1377,
64,
770
],
[
770,
24,
1228
]
],
[
[
1377,
25,
1412
],
[
1412,
63,
1228
]
],
[
[
1377,
24,
242
],
[
242,
63,
1228
]
],
[
[
1377,
63,
1005
],
[
1005,
24,
1228
]
],
[
[
1377,
25,
478
],
[
478,
25,
1228
]
],
[
[
1377,
64,
1176
],
[
1176,
25,
1228
]
]
] | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lenvatinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lenvatinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calaspargase pegol"
],
[
"Calaspargase pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vardenafil"
],
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
]
] | Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Leflunomide may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Leflunomide may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Leflunomide may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Leflunomide may lead to a major life threatening interaction when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Vardenafil and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Leflunomide may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Lenvatinib
Leflunomide may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may lead to a major life threatening interaction when taken with Lenvatinib |
DB00524 | DB00804 | 811 | 1,507 | [
"DDInter1199",
"DDInter543"
] | Metolazone | Dicyclomine | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable. Dicyclomine was granted FDA approval on 11 May 1950. | Minor | 0 | [
[
[
811,
23,
1507
]
],
[
[
811,
21,
28817
],
[
28817,
60,
1507
]
],
[
[
811,
1,
359
],
[
359,
62,
1507
]
],
[
[
811,
40,
1014
],
[
1014,
23,
1507
]
],
[
[
811,
24,
1021
],
[
1021,
63,
1507
]
],
[
[
811,
63,
475
],
[
475,
24,
1507
]
],
[
[
811,
62,
19
],
[
19,
24,
1507
]
],
[
[
811,
23,
85
],
[
85,
24,
1507
]
],
[
[
811,
23,
1511
],
[
1511,
63,
1507
]
],
[
[
811,
25,
1425
],
[
1425,
24,
1507
]
]
] | [
[
[
"Metolazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dicyclomine"
]
],
[
[
"Metolazone",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dicyclomine"
]
],
[
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dicyclomine"
]
],
[
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dicyclomine"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
],
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Metolazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Metolazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Metolazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Metolazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
]
] | Metolazone (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Dicyclomine (Compound)
Metolazone (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Dicyclomine
Metolazone (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Dicyclomine
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine
Metolazone may cause a minor interaction that can limit clinical effects when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine
Metolazone may cause a minor interaction that can limit clinical effects when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine
Metolazone may cause a minor interaction that can limit clinical effects when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine
Metolazone may lead to a major life threatening interaction when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine |
DB01601 | DB06210 | 833 | 72 | [
"DDInter1089",
"DDInter631"
] | Lopinavir | Eltrombopag | Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity. Like many other protease inhibitors (e.g. [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. | Moderate | 1 | [
[
[
833,
24,
72
]
],
[
[
833,
6,
7950
],
[
7950,
45,
72
]
],
[
[
833,
24,
286
],
[
286,
63,
72
]
],
[
[
833,
64,
14
],
[
14,
24,
72
]
],
[
[
833,
1,
350
],
[
350,
64,
72
]
],
[
[
833,
6,
7950
],
[
7950,
45,
1419
],
[
1419,
24,
72
]
],
[
[
833,
24,
286
],
[
286,
24,
971
],
[
971,
63,
72
]
],
[
[
833,
64,
14
],
[
14,
6,
15333
],
[
15333,
45,
72
]
],
[
[
833,
1,
1327
],
[
1327,
6,
15333
],
[
15333,
45,
72
]
],
[
[
833,
1,
350
],
[
350,
24,
384
],
[
384,
63,
72
]
]
] | [
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Lopinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Eltrombopag"
]
],
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Lopinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Lopinavir",
"{u} (Compound) resembles {v} (Compound)",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eltrombopag"
]
],
[
[
"Lopinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Lopinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compound)",
"Eltrombopag"
]
],
[
[
"Lopinavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
],
[
"Saquinavir",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compound)",
"Eltrombopag"
]
],
[
[
"Lopinavir",
"{u} (Compound) resembles {v} (Compound)",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
]
] | Lopinavir (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Eltrombopag (Compound)
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Lopinavir may lead to a major life threatening interaction when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Lopinavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may lead to a major life threatening interaction when taken with Eltrombopag
Lopinavir (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Imatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Lopinavir may lead to a major life threatening interaction when taken with Rosuvastatin and Rosuvastatin (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Eltrombopag (Compound)
Lopinavir (Compound) resembles Saquinavir (Compound) and Saquinavir (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Eltrombopag (Compound)
Lopinavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag |
DB01017 | DB09407 | 1,669 | 853 | [
"DDInter1224",
"DDInter1114"
] | Minocycline | Magnesium chloride | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines. Minocycline was granted FDA approval on 30 June 1971. | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Moderate | 1 | [
[
[
1669,
24,
853
]
],
[
[
1669,
40,
964
],
[
964,
24,
853
]
],
[
[
1669,
63,
544
],
[
544,
24,
853
]
],
[
[
1669,
24,
460
],
[
460,
63,
853
]
],
[
[
1669,
24,
286
],
[
286,
24,
853
]
],
[
[
1669,
1,
1545
],
[
1545,
24,
853
]
],
[
[
1669,
40,
964
],
[
964,
24,
544
],
[
544,
24,
853
]
],
[
[
1669,
63,
544
],
[
544,
24,
1539
],
[
1539,
24,
853
]
],
[
[
1669,
24,
460
],
[
460,
63,
1539
],
[
1539,
24,
853
]
],
[
[
1669,
1,
1545
],
[
1545,
40,
964
],
[
964,
24,
853
]
]
] | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
],
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
],
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
]
] | Minocycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Minocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Minocycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Minocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride |
DB01175 | DB06616 | 318 | 594 | [
"DDInter672",
"DDInter224"
] | Escitalopram | Bosutinib | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment. | Major | 2 | [
[
[
318,
25,
594
]
],
[
[
318,
6,
8374
],
[
8374,
45,
594
]
],
[
[
318,
18,
6351
],
[
6351,
57,
594
]
],
[
[
318,
21,
29231
],
[
29231,
60,
594
]
],
[
[
318,
62,
112
],
[
112,
23,
594
]
],
[
[
318,
63,
1559
],
[
1559,
24,
594
]
],
[
[
318,
24,
1040
],
[
1040,
63,
594
]
],
[
[
318,
62,
597
],
[
597,
24,
594
]
],
[
[
318,
25,
1374
],
[
1374,
24,
594
]
],
[
[
318,
64,
1148
],
[
1148,
24,
594
]
]
] | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Escitalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Escitalopram",
"{u} (Compound) downregulates {v} (Gene)",
"COTL1"
],
[
"COTL1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Escitalopram",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bosutinib"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
]
] | Escitalopram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Escitalopram (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is downregulated by Bosutinib (Compound)
Escitalopram (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound)
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Escitalopram may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Escitalopram may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib |
DB00448 | DB11828 | 1,215 | 1,406 | [
"DDInter1022",
"DDInter1281"
] | Lansoprazole | Neratinib | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion. | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Major | 2 | [
[
[
1215,
25,
1406
]
],
[
[
1215,
24,
392
],
[
392,
24,
1406
]
],
[
[
1215,
63,
1252
],
[
1252,
24,
1406
]
],
[
[
1215,
25,
1195
],
[
1195,
24,
1406
]
],
[
[
1215,
24,
1375
],
[
1375,
63,
1406
]
],
[
[
1215,
24,
283
],
[
283,
64,
1406
]
],
[
[
1215,
24,
609
],
[
609,
25,
1406
]
],
[
[
1215,
40,
379
],
[
379,
25,
1406
]
],
[
[
1215,
23,
697
],
[
697,
25,
1406
]
],
[
[
1215,
63,
529
],
[
529,
25,
1406
]
]
] | [
[
[
"Lansoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Lansoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
]
] | Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lansoprazole may lead to a major life threatening interaction when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Neratinib
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Neratinib
Lansoprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may lead to a major life threatening interaction when taken with Neratinib
Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Phenobarbital and Phenobarbital may lead to a major life threatening interaction when taken with Neratinib
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may lead to a major life threatening interaction when taken with Neratinib |
DB06616 | DB12500 | 594 | 283 | [
"DDInter224",
"DDInter714"
] | Bosutinib | Fedratinib | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
594,
25,
283
]
],
[
[
594,
25,
351
],
[
351,
23,
283
]
],
[
[
594,
64,
122
],
[
122,
23,
283
]
],
[
[
594,
25,
1339
],
[
1339,
62,
283
]
],
[
[
594,
63,
479
],
[
479,
23,
283
]
],
[
[
594,
24,
327
],
[
327,
24,
283
]
],
[
[
594,
64,
1419
],
[
1419,
24,
283
]
],
[
[
594,
63,
336
],
[
336,
24,
283
]
],
[
[
594,
25,
1580
],
[
1580,
24,
283
]
],
[
[
594,
25,
676
],
[
676,
63,
283
]
]
] | [
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
],
[
"Abametapir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
]
] | Bosutinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Bosutinib may lead to a major life threatening interaction when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Bosutinib may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and Abametapir may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Bosutinib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Bosutinib may lead to a major life threatening interaction when taken with Stiripentol and Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Bosutinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib |
DB00681 | DB00703 | 1,287 | 997 | [
"DDInter85",
"DDInter1167"
] | Amphotericin B | Methazolamide | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses. | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Moderate | 1 | [
[
[
1287,
24,
997
]
],
[
[
1287,
24,
471
],
[
471,
1,
997
]
],
[
[
1287,
21,
28792
],
[
28792,
60,
997
]
],
[
[
1287,
63,
175
],
[
175,
24,
997
]
],
[
[
1287,
24,
1486
],
[
1486,
63,
997
]
],
[
[
1287,
25,
497
],
[
497,
63,
997
]
],
[
[
1287,
24,
870
],
[
870,
24,
997
]
],
[
[
1287,
25,
57
],
[
57,
64,
997
]
],
[
[
1287,
24,
471
],
[
471,
5,
11595
],
[
11595,
44,
997
]
],
[
[
1287,
21,
28792
],
[
28792,
60,
471
],
[
471,
1,
997
]
]
] | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
],
[
"Acetazolamide",
"{u} (Compound) resembles {v} (Compound)",
"Methazolamide"
]
],
[
[
"Amphotericin B",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methazolamide"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Amphotericin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Amphotericin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methazolamide"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
],
[
"Acetazolamide",
"{u} (Compound) treats {v} (Disease)",
"glaucoma"
],
[
"glaucoma",
"{u} (Disease) is treated by {v} (Compound)",
"Methazolamide"
]
],
[
[
"Amphotericin B",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Acetazolamide"
],
[
"Acetazolamide",
"{u} (Compound) resembles {v} (Compound)",
"Methazolamide"
]
]
] | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide and Acetazolamide (Compound) resembles Methazolamide (Compound)
Amphotericin B (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Methazolamide (Compound)
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide
Amphotericin B may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide
Amphotericin B may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Methazolamide
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide and Acetazolamide (Compound) treats glaucoma (Disease) and glaucoma (Disease) is treated by Methazolamide (Compound)
Amphotericin B (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Acetazolamide (Compound) and Acetazolamide (Compound) resembles Methazolamide (Compound) |
DB00995 | DB08904 | 1,112 | 375 | [
"DDInter139",
"DDInter342"
] | Auranofin | Certolizumab pegol | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Moderate | 1 | [
[
[
1112,
24,
375
]
],
[
[
1112,
24,
1047
],
[
1047,
24,
375
]
],
[
[
1112,
24,
1434
],
[
1434,
63,
375
]
],
[
[
1112,
63,
10
],
[
10,
24,
375
]
],
[
[
1112,
25,
1487
],
[
1487,
24,
375
]
],
[
[
1112,
63,
63
],
[
63,
25,
375
]
],
[
[
1112,
24,
1480
],
[
1480,
64,
375
]
],
[
[
1112,
64,
1064
],
[
1064,
25,
375
]
],
[
[
1112,
24,
1626
],
[
1626,
25,
375
]
],
[
[
1112,
25,
1377
],
[
1377,
25,
375
]
]
] | [
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
],
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Auranofin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Auranofin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
],
[
"Elotuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Auranofin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
]
] | Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole and Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Auranofin may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may lead to a major life threatening interaction when taken with Certolizumab pegol
Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may lead to a major life threatening interaction when taken with Certolizumab pegol
Auranofin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Certolizumab pegol
Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab and Elotuzumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Auranofin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Certolizumab pegol |
DB00261 | DB00328 | 702 | 831 | [
"DDInter93",
"DDInter921"
] | Anagrelide | Indomethacin | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlorobenzoyl)25-methoxy-2-methylindole-3-acetic acid. The pharmacological effect of indometacin is not fully understood, however, it is thought to be mediated through potent and nonselective inhibition of the enzyme cyclooxygenase (COX), which is the main enzyme responsible for catalyzes the rate-limiting step in prostaglandin and thromboxane biosynthesis via the arachidonic acid (AA) pathway. Indometacin was first discovered in 1963 and it was first approved for use in the U.S. by the Food and Drug Administration in 1965, along with other acetic acid derivatives such as [diclofenac] and [sulindac] that were also developed during the 1960s. Since then, indometacin has been extensively studied in clinical trials as one of the most potent NSAIDs in blocking prostaglandin synthesis and was among the first NSAIDs to be used in the symptomatic treatment of migraine and for headaches that eventually became known as “indomethacin-responsive” headache disorders. Most commonly used in rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute shoulder pains, and acute gouty arthritis, indometacin is currently available as oral capsules as well as other methods of administration, including rectal and intravenous formulations. Intravenous indometacin is administered to close a hemodynamically significant patent ductus arteriosus, as indicated by clinical evidence, in premature infants. Ophthalmic indometacin has been studied and used in the symptomatic treatment of postoperative ocular inflammation and pain and/or complications after cataract surgery. Although deemed effective in reducing ocular inflammation in clinical studies, topical NSAIDs were also associated with a potential reduction in corneal sensitivity accompanied by an increased risk of superficial punctate keratitis and subjective symptoms of discomfort, including pain, burning or pricking, or a tingling sensation after instillation into the cul‐de‐sac. | Moderate | 1 | [
[
[
702,
24,
831
]
],
[
[
702,
24,
1263
],
[
1263,
1,
831
]
],
[
[
702,
21,
29316
],
[
29316,
60,
831
]
],
[
[
702,
24,
752
],
[
752,
62,
831
]
],
[
[
702,
24,
848
],
[
848,
63,
831
]
],
[
[
702,
25,
1555
],
[
1555,
63,
831
]
],
[
[
702,
64,
942
],
[
942,
24,
831
]
],
[
[
702,
25,
291
],
[
291,
24,
831
]
],
[
[
702,
63,
1018
],
[
1018,
24,
831
]
],
[
[
702,
25,
4
],
[
4,
64,
831
]
]
] | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
],
[
"Bromfenac",
"{u} (Compound) resembles {v} (Compound)",
"Indomethacin"
]
],
[
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating"
],
[
"Sweating",
"{u} (Side Effect) is caused by {v} (Compound)",
"Indomethacin"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indomethacin"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Argatroban"
],
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Indomethacin"
]
]
] | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac (Compound) resembles Indomethacin (Compound)
Anagrelide (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Indomethacin (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Indomethacin
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin
Anagrelide may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin
Anagrelide may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin
Anagrelide may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin
Anagrelide may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Indomethacin |
DB00317 | DB15093 | 883 | 1,654 | [
"DDInter810",
"DDInter1698"
] | Gefitinib | Somapacitan | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020. | Moderate | 1 | [
[
[
883,
24,
1654
]
],
[
[
883,
24,
1215
],
[
1215,
24,
1654
]
],
[
[
883,
63,
837
],
[
837,
24,
1654
]
],
[
[
883,
35,
392
],
[
392,
24,
1654
]
],
[
[
883,
1,
594
],
[
594,
24,
1654
]
],
[
[
883,
40,
1069
],
[
1069,
24,
1654
]
],
[
[
883,
63,
1101
],
[
1101,
25,
1654
]
],
[
[
883,
24,
1215
],
[
1215,
24,
467
],
[
467,
24,
1654
]
],
[
[
883,
24,
351
],
[
351,
63,
10
],
[
10,
24,
1654
]
],
[
[
883,
24,
723
],
[
723,
63,
608
],
[
608,
23,
1654
]
]
] | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Somapacitan"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somapacitan"
]
]
] | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Gefitinib (Compound) resembles Lapatinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Gefitinib (Compound) resembles Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Gefitinib (Compound) resembles Vandetanib (Compound) and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somapacitan
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan |
DB00372 | DB00404 | 999 | 523 | [
"DDInter1793",
"DDInter54"
] | Thiethylperazine | Alprazolam | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981. | Moderate | 1 | [
[
[
999,
24,
523
]
],
[
[
999,
63,
905
],
[
905,
40,
523
]
],
[
[
999,
24,
1408
],
[
1408,
1,
523
]
],
[
[
999,
63,
1174
],
[
1174,
1,
523
]
],
[
[
999,
24,
1216
],
[
1216,
40,
523
]
],
[
[
999,
23,
460
],
[
460,
62,
523
]
],
[
[
999,
24,
272
],
[
272,
63,
523
]
],
[
[
999,
63,
1214
],
[
1214,
24,
523
]
],
[
[
999,
25,
593
],
[
593,
63,
523
]
],
[
[
999,
63,
475
],
[
475,
25,
523
]
]
] | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorazepam"
],
[
"Lorazepam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loxapine"
],
[
"Loxapine",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temazepam"
],
[
"Temazepam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
]
],
[
[
"Thiethylperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
],
[
"Magnesium carbonate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alprazolam"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alprazolam"
]
]
] | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Alprazolam (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Loxapine and Loxapine (Compound) resembles Alprazolam (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Temazepam and Temazepam (Compound) resembles Alprazolam (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Alprazolam (Compound)
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate and Magnesium carbonate may cause a minor interaction that can limit clinical effects when taken with Alprazolam
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam
Thiethylperazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Alprazolam |
DB00030 | DB00620 | 1,685 | 175 | [
"DDInter934",
"DDInter1855"
] | Insulin human | Triamcinolone | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis. | Moderate | 1 | [
[
[
1685,
24,
175
]
],
[
[
1685,
24,
1573
],
[
1573,
1,
175
]
],
[
[
1685,
24,
155
],
[
155,
63,
175
]
],
[
[
1685,
23,
1103
],
[
1103,
1,
175
]
],
[
[
1685,
24,
1072
],
[
1072,
62,
175
]
],
[
[
1685,
24,
1523
],
[
1523,
24,
175
]
],
[
[
1685,
63,
305
],
[
305,
24,
175
]
],
[
[
1685,
25,
872
],
[
872,
64,
175
]
],
[
[
1685,
24,
34
],
[
34,
64,
175
]
],
[
[
1685,
24,
798
],
[
798,
25,
175
]
]
] | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxymesterone"
],
[
"Fluoxymesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Insulin human",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triamcinolone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Insulin human",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
],
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
]
]
] | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone and Fluoxymesterone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Insulin human may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) resembles Triamcinolone (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Triamcinolone
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Insulin human may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin may lead to a major life threatening interaction when taken with Triamcinolone
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir may lead to a major life threatening interaction when taken with Triamcinolone
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may lead to a major life threatening interaction when taken with Triamcinolone |
DB01211 | DB11915 | 609 | 1,293 | [
"DDInter393",
"DDInter1909"
] | Clarithromycin | Valbenazine | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective. However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns. On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD). On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial. The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg. | Major | 2 | [
[
[
609,
25,
1293
]
],
[
[
609,
62,
112
],
[
112,
23,
1293
]
],
[
[
609,
24,
710
],
[
710,
63,
1293
]
],
[
[
609,
63,
521
],
[
521,
24,
1293
]
],
[
[
609,
25,
283
],
[
283,
63,
1293
]
],
[
[
609,
25,
392
],
[
392,
24,
1293
]
],
[
[
609,
24,
603
],
[
603,
24,
1293
]
],
[
[
609,
64,
477
],
[
477,
24,
1293
]
],
[
[
609,
62,
222
],
[
222,
24,
1293
]
],
[
[
609,
24,
129
],
[
129,
25,
1293
]
]
] | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Valbenazine"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
],
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
]
] | Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Clarithromycin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Clarithromycin may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Clarithromycin may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Valbenazine |
DB06372 | DB15965 | 259 | 1,330 | [
"DDInter1594",
"DDInter1270"
] | Rilonacept | Naxitamab | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within neuroblastomas (and other neuroectodermal tumors), and is rarely subject to antigen loss. The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies, making the administration of naxitamab therapy markedly simpler than that of its predecessor. | Moderate | 1 | [
[
[
259,
24,
1330
]
],
[
[
259,
23,
1193
],
[
1193,
23,
1330
]
],
[
[
259,
63,
1532
],
[
1532,
24,
1330
]
],
[
[
259,
64,
980
],
[
980,
24,
1330
]
],
[
[
259,
24,
350
],
[
350,
24,
1330
]
],
[
[
259,
25,
375
],
[
375,
25,
1330
]
],
[
[
259,
64,
1066
],
[
1066,
25,
1330
]
],
[
[
259,
23,
1193
],
[
1193,
62,
980
],
[
980,
24,
1330
]
],
[
[
259,
63,
1532
],
[
1532,
63,
597
],
[
597,
24,
1330
]
],
[
[
259,
63,
1686
],
[
1686,
24,
1532
],
[
1532,
24,
1330
]
]
] | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Rilonacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naxitamab"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naxitamab"
]
],
[
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naxitamab"
]
],
[
[
"Rilonacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
],
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
]
] | Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Rilonacept may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Rilonacept may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Naxitamab
Rilonacept may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Naxitamab
Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide and Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab |
DB00781 | DB01337 | 1,481 | 1,579 | [
"DDInter1489",
"DDInter1385"
] | Polymyxin B | Pancuronium | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of _Pseudomonas aeruginosa_[FDA Label]. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line. | A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release. | Major | 2 | [
[
[
1481,
25,
1579
]
],
[
[
1481,
64,
1610
],
[
1610,
1,
1579
]
],
[
[
1481,
25,
728
],
[
728,
1,
1579
]
],
[
[
1481,
21,
28717
],
[
28717,
60,
1579
]
],
[
[
1481,
63,
91
],
[
91,
24,
1579
]
],
[
[
1481,
1,
1441
],
[
1441,
24,
1579
]
],
[
[
1481,
25,
1448
],
[
1448,
25,
1579
]
],
[
[
1481,
64,
1610
],
[
1610,
1,
1665
],
[
1665,
1,
1579
]
],
[
[
1481,
25,
728
],
[
728,
40,
1665
],
[
1665,
1,
1579
]
],
[
[
1481,
21,
28717
],
[
28717,
60,
728
],
[
728,
1,
1579
]
]
] | [
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pancuronium"
]
],
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rocuronium"
],
[
"Rocuronium",
"{u} (Compound) resembles {v} (Compound)",
"Pancuronium"
]
],
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vecuronium"
],
[
"Vecuronium",
"{u} (Compound) resembles {v} (Compound)",
"Pancuronium"
]
],
[
[
"Polymyxin B",
"{u} (Compound) causes {v} (Side Effect)",
"Flushing"
],
[
"Flushing",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pancuronium"
]
],
[
[
"Polymyxin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
],
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pancuronium"
]
],
[
[
"Polymyxin B",
"{u} (Compound) resembles {v} (Compound)",
"Bacitracin"
],
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pancuronium"
]
],
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pancuronium"
]
],
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rocuronium"
],
[
"Rocuronium",
"{u} (Compound) resembles {v} (Compound)",
"Pipecuronium"
],
[
"Pipecuronium",
"{u} (Compound) resembles {v} (Compound)",
"Pancuronium"
]
],
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vecuronium"
],
[
"Vecuronium",
"{u} (Compound) resembles {v} (Compound)",
"Pipecuronium"
],
[
"Pipecuronium",
"{u} (Compound) resembles {v} (Compound)",
"Pancuronium"
]
],
[
[
"Polymyxin B",
"{u} (Compound) causes {v} (Side Effect)",
"Flushing"
],
[
"Flushing",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vecuronium"
],
[
"Vecuronium",
"{u} (Compound) resembles {v} (Compound)",
"Pancuronium"
]
]
] | Polymyxin B may lead to a major life threatening interaction when taken with Rocuronium and Rocuronium (Compound) resembles Pancuronium (Compound)
Polymyxin B may lead to a major life threatening interaction when taken with Vecuronium and Vecuronium (Compound) resembles Pancuronium (Compound)
Polymyxin B (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Pancuronium (Compound)
Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium
Polymyxin B (Compound) resembles Bacitracin (Compound) and Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium
Polymyxin B may lead to a major life threatening interaction when taken with Streptomycin and Streptomycin may lead to a major life threatening interaction when taken with Pancuronium
Polymyxin B may lead to a major life threatening interaction when taken with Rocuronium and Rocuronium (Compound) resembles Pipecuronium (Compound) and Pipecuronium (Compound) resembles Pancuronium (Compound)
Polymyxin B may lead to a major life threatening interaction when taken with Vecuronium and Vecuronium (Compound) resembles Pipecuronium (Compound) and Pipecuronium (Compound) resembles Pancuronium (Compound)
Polymyxin B (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Vecuronium (Compound) and Vecuronium (Compound) resembles Pancuronium (Compound) |
DB00855 | DB12329 | 213 | 464 | [
"DDInter72",
"DDInter660"
] | Aminolevulinic acid | Eravacycline | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections . | Major | 2 | [
[
[
213,
25,
464
]
],
[
[
213,
64,
92
],
[
92,
24,
464
]
],
[
[
213,
36,
842
],
[
842,
24,
464
]
],
[
[
213,
25,
1517
],
[
1517,
25,
464
]
],
[
[
213,
64,
1101
],
[
1101,
25,
464
]
],
[
[
213,
64,
92
],
[
92,
24,
1517
],
[
1517,
25,
464
]
],
[
[
213,
36,
842
],
[
842,
63,
1101
],
[
1101,
25,
464
]
],
[
[
213,
25,
1517
],
[
1517,
24,
384
],
[
384,
23,
464
]
],
[
[
213,
64,
1101
],
[
1101,
23,
609
],
[
609,
23,
464
]
],
[
[
213,
21,
28803
],
[
28803,
60,
609
],
[
609,
23,
464
]
]
] | [
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eravacycline"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methoxsalen"
],
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eravacycline"
]
],
[
[
"Aminolevulinic acid",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Methyl aminolevulinate"
],
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eravacycline"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isotretinoin"
],
[
"Isotretinoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eravacycline"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eravacycline"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methoxsalen"
],
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
],
[
"Isotretinoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eravacycline"
]
],
[
[
"Aminolevulinic acid",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Methyl aminolevulinate"
],
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eravacycline"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isotretinoin"
],
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eravacycline"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eravacycline"
]
],
[
[
"Aminolevulinic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Anaemia"
],
[
"Anaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eravacycline"
]
]
] | Aminolevulinic acid may lead to a major life threatening interaction when taken with Methoxsalen and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Eravacycline
Aminolevulinic acid (Compound) resembles Methyl aminolevulinate (Compound) and Aminolevulinic acid may lead to a major life threatening interaction when taken with Methyl aminolevulinate and Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Eravacycline
Aminolevulinic acid may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin may lead to a major life threatening interaction when taken with Eravacycline
Aminolevulinic acid may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Eravacycline
Aminolevulinic acid may lead to a major life threatening interaction when taken with Methoxsalen and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin and Isotretinoin may lead to a major life threatening interaction when taken with Eravacycline
Aminolevulinic acid (Compound) resembles Methyl aminolevulinate (Compound) and Aminolevulinic acid may lead to a major life threatening interaction when taken with Methyl aminolevulinate and Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Eravacycline
Aminolevulinic acid may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Eravacycline
Aminolevulinic acid may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Eravacycline
Aminolevulinic acid (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Eravacycline |
DB00211 | DB00863 | 1,290 | 1,194 | [
"DDInter1213",
"DDInter1568"
] | Midodrine | Ranitidine | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818] | Minor | 0 | [
[
[
1290,
23,
1194
]
],
[
[
1290,
6,
12523
],
[
12523,
45,
1194
]
],
[
[
1290,
21,
28722
],
[
28722,
60,
1194
]
],
[
[
1290,
24,
478
],
[
478,
63,
1194
]
],
[
[
1290,
63,
352
],
[
352,
24,
1194
]
],
[
[
1290,
23,
1645
],
[
1645,
24,
1194
]
],
[
[
1290,
6,
12523
],
[
12523,
45,
798
],
[
798,
23,
1194
]
],
[
[
1290,
21,
28722
],
[
28722,
60,
1127
],
[
1127,
1,
1194
]
],
[
[
1290,
21,
28695
],
[
28695,
60,
59
],
[
59,
23,
1194
]
],
[
[
1290,
24,
478
],
[
478,
63,
1127
],
[
1127,
1,
1194
]
]
] | [
[
[
"Midodrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
]
],
[
[
"Midodrine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Ranitidine"
]
],
[
[
"Midodrine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ranitidine"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
]
],
[
[
"Midodrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
]
],
[
[
"Midodrine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
]
],
[
[
"Midodrine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nizatidine"
],
[
"Nizatidine",
"{u} (Compound) resembles {v} (Compound)",
"Ranitidine"
]
],
[
[
"Midodrine",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etodolac"
],
[
"Etodolac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nizatidine"
],
[
"Nizatidine",
"{u} (Compound) resembles {v} (Compound)",
"Ranitidine"
]
]
] | Midodrine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ranitidine (Compound)
Midodrine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Ranitidine (Compound)
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine
Midodrine may cause a minor interaction that can limit clinical effects when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine
Midodrine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nelfinavir (Compound) and Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Midodrine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Nizatidine (Compound) and Nizatidine (Compound) resembles Ranitidine (Compound)
Midodrine (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Etodolac (Compound) and Etodolac may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Nizatidine and Nizatidine (Compound) resembles Ranitidine (Compound) |
DB00621 | DB01095 | 1,026 | 671 | [
"DDInter1357",
"DDInter769"
] | Oxandrolone | Fluvastatin | A synthetic hormone with anabolic and androgenic properties. | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class. Fluvastatin is a racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin. | Moderate | 1 | [
[
[
1026,
24,
671
]
],
[
[
1026,
7,
7310
],
[
7310,
46,
671
]
],
[
[
1026,
18,
3616
],
[
3616,
57,
671
]
],
[
[
1026,
21,
28698
],
[
28698,
60,
671
]
],
[
[
1026,
25,
126
],
[
126,
23,
671
]
],
[
[
1026,
63,
322
],
[
322,
24,
671
]
],
[
[
1026,
24,
1613
],
[
1613,
63,
671
]
],
[
[
1026,
24,
267
],
[
267,
24,
671
]
],
[
[
1026,
25,
350
],
[
350,
63,
671
]
],
[
[
1026,
25,
1510
],
[
1510,
64,
671
]
]
] | [
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Oxandrolone",
"{u} (Compound) upregulates {v} (Gene)",
"KLHL9"
],
[
"KLHL9",
"{u} (Gene) is upregulated by {v} (Compound)",
"Fluvastatin"
]
],
[
[
"Oxandrolone",
"{u} (Compound) downregulates {v} (Gene)",
"CDC45"
],
[
"CDC45",
"{u} (Gene) is downregulated by {v} (Compound)",
"Fluvastatin"
]
],
[
[
"Oxandrolone",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fluvastatin"
]
],
[
[
"Oxandrolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluvastatin"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Oxandrolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Oxandrolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvastatin"
]
]
] | Oxandrolone (Compound) upregulates KLHL9 (Gene) and KLHL9 (Gene) is upregulated by Fluvastatin (Compound)
Oxandrolone (Compound) downregulates CDC45 (Gene) and CDC45 (Gene) is downregulated by Fluvastatin (Compound)
Oxandrolone (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Fluvastatin (Compound)
Oxandrolone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Fluvastatin
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin
Oxandrolone may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin
Oxandrolone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Fluvastatin |
DB00317 | DB01115 | 883 | 336 | [
"DDInter810",
"DDInter1291"
] | Gefitinib | Nifedipine | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981. | Moderate | 1 | [
[
[
883,
24,
336
]
],
[
[
883,
6,
4973
],
[
4973,
45,
336
]
],
[
[
883,
18,
8386
],
[
8386,
46,
336
]
],
[
[
883,
7,
4634
],
[
4634,
57,
336
]
],
[
[
883,
18,
10699
],
[
10699,
57,
336
]
],
[
[
883,
21,
28695
],
[
28695,
60,
336
]
],
[
[
883,
24,
1194
],
[
1194,
23,
336
]
],
[
[
883,
24,
98
],
[
98,
63,
336
]
],
[
[
883,
24,
752
],
[
752,
24,
336
]
],
[
[
883,
63,
1324
],
[
1324,
24,
336
]
]
] | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Nifedipine"
]
],
[
[
"Gefitinib",
"{u} (Compound) downregulates {v} (Gene)",
"MTHFD2"
],
[
"MTHFD2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Nifedipine"
]
],
[
[
"Gefitinib",
"{u} (Compound) upregulates {v} (Gene)",
"FOXO4"
],
[
"FOXO4",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nifedipine"
]
],
[
[
"Gefitinib",
"{u} (Compound) downregulates {v} (Gene)",
"KIF20A"
],
[
"KIF20A",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nifedipine"
]
],
[
[
"Gefitinib",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nifedipine"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nifedipine"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
]
] | Gefitinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nifedipine (Compound)
Gefitinib (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Nifedipine (Compound)
Gefitinib (Compound) upregulates FOXO4 (Gene) and FOXO4 (Gene) is downregulated by Nifedipine (Compound)
Gefitinib (Compound) downregulates KIF20A (Gene) and KIF20A (Gene) is downregulated by Nifedipine (Compound)
Gefitinib (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Nifedipine (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Nifedipine
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine |
DB00022 | DB01125 | 268 | 279 | [
"DDInter1408",
"DDInter98"
] | Peginterferon alfa-2b | Anisindione | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver. | Moderate | 1 | [
[
[
268,
24,
279
]
],
[
[
268,
24,
467
],
[
467,
23,
279
]
],
[
[
268,
24,
912
],
[
912,
24,
279
]
],
[
[
268,
25,
593
],
[
593,
63,
279
]
],
[
[
268,
23,
450
],
[
450,
24,
279
]
],
[
[
268,
25,
1377
],
[
1377,
24,
279
]
],
[
[
268,
63,
491
],
[
491,
24,
279
]
],
[
[
268,
24,
738
],
[
738,
63,
279
]
],
[
[
268,
24,
4
],
[
4,
64,
279
]
],
[
[
268,
24,
112
],
[
112,
25,
279
]
]
] | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Anisindione"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
]
] | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Anisindione
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Peginterferon alfa-2b may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Anisindione
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may lead to a major life threatening interaction when taken with Anisindione |
DB00197 | DB01577 | 1,324 | 1,529 | [
"DDInter1881",
"DDInter1161"
] | Troglitazone | Metamfetamine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse. The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt. | Moderate | 1 | [
[
[
1324,
24,
1529
]
],
[
[
1324,
24,
939
],
[
939,
40,
1529
]
],
[
[
1324,
24,
22
],
[
22,
24,
1529
]
],
[
[
1324,
24,
1281
],
[
1281,
63,
1529
]
],
[
[
1324,
63,
1179
],
[
1179,
24,
1529
]
],
[
[
1324,
24,
222
],
[
222,
25,
1529
]
],
[
[
1324,
24,
1445
],
[
1445,
35,
1529
]
],
[
[
1324,
24,
1466
],
[
1466,
36,
1529
]
],
[
[
1324,
63,
73
],
[
73,
36,
1529
]
],
[
[
1324,
24,
939
],
[
939,
1,
1161
],
[
1161,
40,
1529
]
]
] | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Metamfetamine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metamfetamine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Metamfetamine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Metamfetamine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Selegiline"
],
[
"Selegiline",
"{u} (Compound) resembles {v} (Compound)",
"Metamfetamine"
]
]
] | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Metamfetamine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Metamfetamine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Metamfetamine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine (Compound) resembles Metamfetamine (Compound) and Phenylpropanolamine may lead to a major life threatening interaction when taken with Metamfetamine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Metamfetamine (Compound) and Phentermine may lead to a major life threatening interaction when taken with Metamfetamine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Selegiline (Compound) and Selegiline (Compound) resembles Metamfetamine (Compound) |
DB00860 | DB01278 | 891 | 1,021 | [
"DDInter1513",
"DDInter1506"
] | Prednisolone | Pramlintide | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
891,
24,
1021
]
],
[
[
891,
40,
1103
],
[
1103,
23,
1021
]
],
[
[
891,
63,
1560
],
[
1560,
24,
1021
]
],
[
[
891,
24,
1680
],
[
1680,
24,
1021
]
],
[
[
891,
64,
839
],
[
839,
24,
1021
]
],
[
[
891,
25,
1539
],
[
1539,
24,
1021
]
],
[
[
891,
24,
35
],
[
35,
63,
1021
]
],
[
[
891,
40,
1573
],
[
1573,
24,
1021
]
],
[
[
891,
23,
688
],
[
688,
24,
1021
]
],
[
[
891,
25,
255
],
[
255,
63,
1021
]
]
] | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pramlintide"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
],
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
]
] | Prednisolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Pramlintide
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Prednisolone may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Prednisolone may lead to a major life threatening interaction when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Prednisolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Prednisolone may lead to a major life threatening interaction when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.